<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002090.pub2" GROUP_ID="STROKE" ID="646099111615583841" MERGED_FROM="" MODIFIED="2008-07-16 11:55:02 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-07-16 11:55:02 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Amphetamines for improving recovery after stroke</TITLE>
<CONTACT MODIFIED="2008-07-16 11:55:02 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16507" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Louise</FIRST_NAME><LAST_NAME>Martinsson</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Study Delivery Operations Specialist</POSITION><EMAIL_1>louise.martinsson@astrazeneca.com</EMAIL_1><ADDRESS><DEPARTMENT>R&amp;D Södertälje, Study Delivery II</DEPARTMENT><ORGANISATION>AstraZeneca</ORGANISATION><CITY>Södertälje</CITY><ZIP>SE-151 85</ZIP><COUNTRY CODE="SE">Sweden</COUNTRY><PHONE_1>+46 8 553 21197</PHONE_1><FAX_1>+46 8 553 289 34</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-07-16 11:55:02 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16507" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Louise</FIRST_NAME><LAST_NAME>Martinsson</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Study Delivery Operations Specialist</POSITION><EMAIL_1>louise.martinsson@astrazeneca.com</EMAIL_1><ADDRESS><DEPARTMENT>R&amp;D Södertälje, Study Delivery II</DEPARTMENT><ORGANISATION>AstraZeneca</ORGANISATION><CITY>Södertälje</CITY><ZIP>SE-151 85</ZIP><COUNTRY CODE="SE">Sweden</COUNTRY><PHONE_1>+46 8 553 21197</PHONE_1><FAX_1>+46 8 553 289 34</FAX_1></ADDRESS></PERSON><PERSON ID="16493" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Hans-Göran</FIRST_NAME><LAST_NAME>Hårdemark</LAST_NAME><POSITION>Senior Physician</POSITION><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Hospital</ORGANISATION><CITY>Uppsala</CITY><ZIP>751 85</ZIP><COUNTRY CODE="SE">Sweden</COUNTRY><PHONE_1>+46 18 6110000</PHONE_1></ADDRESS></PERSON><PERSON ID="BBDCFA7882E26AA200831C194F390448" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Staffan</FIRST_NAME><LAST_NAME>Eksborg</LAST_NAME><POSITION>Associate Professor</POSITION><ADDRESS><DEPARTMENT>Department of Woman and Child Health, Karolinska Pharmacy and Childhood Cancer Research Unit</DEPARTMENT><ORGANISATION>Karolinska Institute</ORGANISATION><CITY>Stockholm</CITY><ZIP>17176</ZIP><COUNTRY CODE="SE">Sweden</COUNTRY><PHONE_1>+46 8 517 753 30</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-16 10:07:52 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="9" MONTH="9" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="1" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-07-16 10:09:11 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="15" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-07-16 10:10:15 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-07-16 10:08:09 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="9" MONTH="9" YEAR="2006"/>
<DESCRIPTION>
<P>Change to authorship</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-16 10:10:15 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="9" MONTH="9" YEAR="2006"/>
<DESCRIPTION>
<P>Differences between this review and the previous version (The Cochrane Library Issue 3, 2003)</P>
<P>The references in the background section have been updated where relevant.</P>
<P>Subheadings have been added under 'Description of studies' to make this section more clear. The section 'Methodological quality of included studies' is more detailed with more information about the different quality aspects of the trials that were assessed when including them in the review. The 'Plain language summary' has been rewritten.</P>
<P>One trial (Gladstone 2006) was moved from the 'Ongoing studies' section to the 'Included studies' section. Two more studies (Platz 2005; Treig 2003) were added in the 'Included studies' section. With the inclusion of these trials, the number of patients in this review has increased from 172 to 287.</P>
<P>Three studies (Mazagri 1995; Unwin 2000; Volpe 2000) have been moved from 'Awaiting assessment' to 'Excluded', as no data have been received despite repeated requests to the authors. Data are no longer available from one of the studies (Mazagri 1995) according to one of the authors.</P>
<P>One study by Cohen L et al has been deleted from 'Ongoing studies'. The study 'Neuroanatomical and neuropsychological basis of motor recovery associated with treatment of recent stroke using amphetamine with physical therapy' was terminated prematurely due to recruitment problems. Another study by L Cohen, 'Improvement of use dependent plasticity in chronic stroke', has been added to 'Ongoing studies'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-16 10:48:43 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY>
<TITLE>Amphetamines for improving recovery after stroke</TITLE>
<SUMMARY_BODY>
<P>A stroke interrupts the blood flow to the brain, often leading to damage to some functions of the brain. This can cause persisting paralysis of some parts of the body or other difficulties with various physical functions. Experiments in animals have shown that amphetamines (stimulants) might be able to improve recovery from stroke. The mechanisms behind the faster recovery seen after stroke in animals are not clearly understood. This review identified 10 small randomized trials of amphetamines in patients with stroke. There was no evidence that amphetamines did more good than harm. There is not enough evidence to support the routine use of amphetamines to promote recovery after stroke. Further controlled trials are needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-16 10:11:06 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND>
<P>Animal research shows that treatment with amphetamines improves recovery after focal cerebral ischaemia. If the effects are similar in humans, amphetamine treatment could have a major impact on recovery from stroke. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of amphetamine treatment in patients with stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-16 10:11:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (last searched January 2006), the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> Issue 1, 2006), MEDLINE (1966 to January 2006), EMBASE (1980 to January 2006), CINAHL (1982 to January 2006), CINAHL (1982 to January 2006), Science Citation Index (1992 to March 2005) and registers of ongoing trials. We also checked the reference lists of all relevant articles and reviews, and contacted researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized unconfounded trials comparing amphetamine with placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently selected trials for inclusion and assessed trial quality; one extracted the data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Ten studies involving 287 patients were included, but not all trials contributed data to each outcome examined in this review. The quality of the trials varied but was generally high. Based on three trials (106 patients) there was no evidence that amphetamine treatment reduced death or dependence (Peto's odds ratio (Peto OR) 1.5, 95% confidence interval (CI) 0.6 to 3.3). Imbalances at baseline with more serious stroke allocated to amphetamine may account for the trend for more deaths at the end of follow up among amphetamine-allocated patients (Peto OR 2.8, 95% CI 0.9 to 8.6). Based on two trials (73 patients) systolic (weighted mean difference (WMD) 8.4 mm Hg, 95% CI 1.6 to 15.2) and diastolic (WMD 4.9 mm Hg, 95% CI 1.1 to 8.8) blood pressure, as well as heart rate, increased (WMD 10.6 bpm, 95% CI 3.3 to 17.8) in amphetamine-allocated patients. Based on six studies (176 patients) there was evidence of a better relative change from baseline to last follow up in motor function (WMD -6.1 points; 95% CI -10.4 to -1.9) Different results with different analysis approaches emphasize caution in the interpretation of the results.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>At present, too few patients have been studied to draw any definite conclusions about the effects of amphetamine treatment on recovery from stroke. The suggested benefits on motor function and the non-significant trend towards increased risk of death could be related to imbalances in prognostic variables or other bias in the studies. Further research is therefore justified. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-16 10:48:43 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND>
<P>Stroke is the second leading cause of death in industrialized countries, the leading cause of adult disability (<LINK REF="REF-Mackay-2004" TYPE="REFERENCE">Mackay 2004</LINK>), and a major cause of acute and long-stay hospital resource consumption in Western society (<LINK REF="REF-Bonita-1992" TYPE="REFERENCE">Bonita 1992</LINK>). Although stroke units reduce mortality and improve functional outcome after stroke (<LINK REF="REF-Stroke-Unit-2001" TYPE="REFERENCE">Stroke Unit 2001</LINK>), about one third of patients who sustain a stroke will survive with considerable residual disability (<LINK REF="REF-Wade-1992" TYPE="REFERENCE">Wade 1992</LINK>). </P>
<P>Most clinical trials of pharmacological agents in acute stroke have focused on mechanisms that occur in the very acute stage of stroke, such as restoration of blood flow with thrombolytic therapy, or reducing the effects of ischaemia by neuroprotective therapy. Unfortunately, though, thrombolytic therapy can only be given to highly selected patients (<LINK REF="REF-Wardlaw-2003" TYPE="REFERENCE">Wardlaw 2003</LINK>) and until now, the evidence of efficacy with neuroprotective treatment in humans is essentially lacking (<LINK REF="REF-Gladstone-2002" TYPE="REFERENCE">Gladstone 2002</LINK>), although one candidate is promising (<LINK REF="REF-Lees-2006" TYPE="REFERENCE">Lees 2006</LINK>). Thus, there is a need for new pharmacological strategies that can be used in both the acute and chronic stages to improve outcome after stroke. Efforts to find pharmacological treatments affecting the recovery processes in humans have been scarce despite the time window for potential therapeutic benefit being wider than thrombolytic therapy and consequently a larger absolute benefit of treatment. Accumulating evidence suggests that neurological recovery continues for days, weeks and even months after stroke, and is caused by, amongst other factors, central nervous reorganisation (<LINK REF="REF-Nudo-2003" TYPE="REFERENCE">Nudo 2003</LINK>). </P>
<P>Several pharmacological approaches to affect the recovery process after a stroke have been tried in animal laboratory settings (<LINK REF="REF-Goldstein-1998" TYPE="REFERENCE">Goldstein 1998</LINK>). Some drugs have been shown to enhance recovery while others might have an opposite effect (<LINK REF="REF-Goldstein-1998" TYPE="REFERENCE">Goldstein 1998</LINK>). Treatment with amphetamines is one of the most extensively studied pharmacological approaches to affect recovery after experimental stroke. Amphetamines are a group of closely related synthetic drugs that stimulate the central and peripheral nervous system. The racemic (d,l-amphetamine), dexamphetamine (also called dextroamphetamine) and methamphetamine have been tried in patients with stroke. Of the three, dexamphetamine is considered the most powerful central nervous system stimulant, with methamphetamine being intermediate and the racemic form the less powerful central stimulant. The racemic form is the most potent in terms of peripheral actions (<LINK REF="REF-Kornetsky-1969" TYPE="REFERENCE">Kornetsky 1969</LINK>). In animal and human studies of recovery from stroke, dexamphetamine is the most commonly used agent. Common side effects of amphetamines are nervousness, insomnia, loss of appetite, and addiction. It is possible that amphetamine can cause stroke in young patients (<LINK REF="REF-Petitti-1998" TYPE="REFERENCE">Petitti 1998</LINK>). </P>
<P>The positive effect on recovery seen with treatment with amphetamines is believed to be caused by an effect on the neurotransmitter noradrenaline in the central nervous system (<LINK REF="REF-Feeney-1998a" TYPE="REFERENCE">Feeney 1998a</LINK>). Animal experimental studies suggest that noradrenergic drugs, such as amphetamine, can enhance functional behaviour after stroke, particularly if the pharmacological treatment is combined with physical activity (<LINK REF="REF-Feeney-1998b" TYPE="REFERENCE">Feeney 1998b</LINK>). An interesting aspect of this treatment is that enhanced functional recovery has been obtained even weeks after stroke onset (<LINK REF="REF-Feeney-1998b" TYPE="REFERENCE">Feeney 1998b</LINK>). A single dose of dexamphetamine resulted in an enduring enhancement of motor recovery in rats with unilateral sensorimotor cortex ablation (<LINK REF="REF-Feeney-1982" TYPE="REFERENCE">Feeney 1982</LINK>). Other studies have shown that this effect of amphetamine extends both to functional deficits that occur following focal lesions produced through a variety of mechanisms, and to abnormal behaviour following lesions affecting other areas of the cortex (<LINK REF="REF-Adkins-2005" TYPE="REFERENCE">Adkins 2005</LINK>; <LINK REF="REF-Feeney-1988" TYPE="REFERENCE">Feeney 1988</LINK>; <LINK REF="REF-Gilmour-2005" TYPE="REFERENCE">Gilmour 2005</LINK>; <LINK REF="REF-Goldstein-1990" TYPE="REFERENCE">Goldstein 1990</LINK>; <LINK REF="REF-Hurwitz-1991" TYPE="REFERENCE">Hurwitz 1991</LINK>; <LINK REF="REF-Stroemer-1994" TYPE="REFERENCE">Stroemer 1994</LINK>). It has been shown that the functional improvement in dexamphetamine treated rats is associated with increased density of synapses (<LINK REF="REF-Stroemer-1998" TYPE="REFERENCE">Stroemer 1998</LINK>), which presumably facilitates recovery of neuronal activity (<LINK REF="REF-Stroemer-1998" TYPE="REFERENCE">Stroemer 1998</LINK>). However, laboratory experiments have shown that the effects of amphetamines only occur within a narrow dose range and do not demonstrate the same level of recovery after all sorts of cerebral lesions. Amphetamines can even worsen the deficits (<LINK REF="REF-Boyeson-1991" TYPE="REFERENCE">Boyeson 1991</LINK>; <LINK REF="REF-Brown-2004" TYPE="REFERENCE">Brown 2004</LINK>; <LINK REF="REF-Mintz-1986" TYPE="REFERENCE">Mintz 1986</LINK>). </P>
<P>During the last decade, a few clinical trials have been published on the effects of amphetamines on stroke recovery. Given the large potential for enhancing recovery after stroke but also the risk of adverse effects, a systematic review of all available randomized evidence is warranted to see if amphetamines are beneficial following stroke. </P>
<P>This is a scheduled update of the first review published in 2003. </P>
</BACKGROUND>
<OBJECTIVES>
<P>The key objectives of this review were to investigate the following hypotheses.<BR/>(1) Amphetamines reduce death and disability in stroke patients (including ischaemic and haemorrhagic subtypes) irrespective of the delay between the onset of symptoms and the start of treatment as compared to control.<BR/>(2) Administration of amphetamines is not associated with any intolerable adverse effects (according to separate specification). <BR/>(3) The efficacy and safety of amphetamines are the same, whether (a) treatment is started in the acute phase (within three weeks), the subacute phase (between three weeks and three months), or in the chronic phase (after three months), and whether (b) the stroke is ischaemic or haemorrhagic in origin. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-16 10:32:47 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All unconfounded randomized trials comparing amphetamine with placebo or open control were included if they evaluated the effect on outcome after stroke. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients were included if they had a diagnosis of stroke that fulfilled the clinical criteria of the World Health Organization of 'Rapidly developed clinical signs of focal (or global) disturbances of cerebral function, lasting more than 24 hours or leading to death, with no other apparent cause than of vascular origin' (<LINK REF="REF-WHO-1989" TYPE="REFERENCE">WHO 1989</LINK>) with or without confirmation by computed tomography (CT) scan or magnetic resonance imaging (MRI). Patients with ischaemic as well as haemorrhagic stroke but not subarachnoid haemorrhage were considered for inclusion in the review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Treatment with all kinds of amphetamines, regardless of dose, duration, and route, were accepted. Time from onset to start of treatment was derived in (1) acute phase (within three weeks), (2) subacute phase (between three weeks and three months), or (3) chronic phase (after three months).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcome, death or dependency, was evaluated at the final study follow up. None of the studies included in the review had longer follow ups than one year. Dependency was defined on the basis of scores from scales used in studies that corresponded to less than 60 out of the top score of 100 (<LINK REF="REF-Sulter-1999" TYPE="REFERENCE">Sulter 1999</LINK>) on the Barthel Index (<LINK REF="REF-Mahoney-1965" TYPE="REFERENCE">Mahoney 1965</LINK>), or the Oxford Handicap scale grades 3 to 6 (<LINK REF="REF-Bamford-1989" TYPE="REFERENCE">Bamford 1989</LINK>) from a top score of 0 (no dependency). Analysis of cause-specific deaths was not undertaken. Measures of motor function, neurological function, language function, activities of daily living (ADL), depression, cognitive functions, and sensation were taken from each trial. Originally the intention was to review reports on the following adverse events: insomnia, nervousness, hallucinations, agitation, euphoria, dysphoria, diarrhoea, loss of appetite, addiction, hypertension, hypotension, hyperthermia, hypothermia, recurrence of stroke, and death. Instead, all adverse events, irrespective of whether or not assessments were pre-specified in trials, are included. The adverse events are listed according to incidence rate since we consider it important to report on all events mentioned in the trials. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-16 10:32:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>We searched the Cochrane Stroke Group Trials Register which was last searched by the Review Group Co-ordinator in January 2006. In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 1, 2006), MEDLINE (1966 to January 2006) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), EMBASE (1980 to January 2006), CINAHL (1982 to January 2006), Science Citation Index (1992 to December 2005), CINAHL (1982 to January 2006), Science Citation Index (1992 to March 2005) and the following registers of ongoing trials:<BR/>
</P>
<UL>
<LI>ClinicalTrials.gov (http:/www.clinicaltrials.gov/)</LI>
<LI>Current Controlled Trials (http://www.controlled-trials.com/)</LI>
<LI>NIH Clinical Center Trials Register (Http://clinicalstudies.info.nih.gov/)</LI>
<LI>Stroke Trials Registry (http://www.strokecenter.org/trials/index.aspx)</LI>
</UL>
<P>In an effort to identify further published and unpublished and ongoing trials, we checked the reference lists of all relevant articles identified, including reviews, and contacted authors of published trials and other researchers. No contact was made with pharmaceutical companies.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two review authors independently checked all titles and abstracts identified by the searches. The full text of an article was only retrieved if there was any doubt as to whether the article should be excluded or not. In case of disagreement between the two review authors, a third member of the research group reviewed the information to decide on inclusion or exclusion of an abstract. </P>
<P>We assessed the methodological quality of the included trials with particular emphasis on allocation concealment, which was ranked using the Cochrane approach: Grade A - adequate concealment; Grade B - uncertain; Grade C - clearly inadequate concealment. Where there was uncertainty, we contacted study authors for clarification. We further assessed the methodological quality of studies using the following criteria: baseline comparison of experimental groups, explicit diagnostic criteria, completeness of follow ups, blind outcome assessment; and blinded administration of the drug.</P>
<P>Two review authors independently performed data extraction and contacted study authors to obtain missing data where possible. </P>
<P>The Cochrane Collaboration's Review Manager software, RevMan 4.2, was used to calculate treatment effects across trials. The results are expressed as Peto's odds ratio (Peto OR) and 95% confidence intervals (CI) for dichotomous outcomes. For continuous data, weighted mean differences (WMD) with a fixed-effect model were used for all analyses except the motor function data where a standardized mean difference was used (SMD) since the outcome scales were not the same in the studies contributing data to the analysis. </P>
<P>We attempted to do subgroup analyses to compare effects in patients with different times to start of the treatment, dosage, length of treatment, stroke subtypes, and severity at baseline. However, the small number of studies and number of patients included did not allow any meaningful conclusions to be drawn. We performed an intention-to-treat (ITT) analysis (<LINK REF="REF-Montori-2001" TYPE="REFERENCE">Montori 2001</LINK>) for the different outcomes where data were available (motor score, ADL, neurological function, language function, and depression), but data for one placebo patient (<LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>) was missing. Patients who died were given a score one point below the lowest score. The main analyses, however, are based on surviving patients excluding five placebo allocated patients (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>, n = 1 (total n = 71); <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>, n = 3 (total n = 26); <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>, n = 1 (total n = 40)), and 12 amphetamine-allocated patients (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>, n = 3 (total n = 71); <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>, n = 8 (total n = 26); <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>, n = 1 (total n = 21)), who did not complete treatment or follow up.</P>
<P>In studies where individual data were available, a transformed score (<LINK REF="REF-Gelmers-1988" TYPE="REFERENCE">Gelmers 1988</LINK>) was analysed, in addition to means and standard deviations of the raw scores. This procedure provided adjustments for baseline differences in several studies (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>). The transformed score was calculated according to a previously used algorithm (<LINK REF="REF-Gelmers-1988" TYPE="REFERENCE">Gelmers 1988</LINK>) and ranged from -100 (maximal worsening) to +100 (maximal improvement). The transformed score takes into account that the maximal possible decrease or increase in score is related to the patient's baseline score.</P>
<P>Assessments of the effects of treatment of blood pressure and heart rate were included from two studies (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>). Besides the raw data the results reported, were on so-called difference data due to differences between amphetamine and placebo-treated patients at baseline in one of the studies (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). The score was calculated by subtracting the baseline value from the value at each assessment point. The mean of the difference scores was used in the analysis. </P>
<P>The heterogeneity between trial results was tested for using a standard chi-square test, with a threshold value of P &lt; 0.1. Heterogeneity was found in the analysis of heart rate during treatment. A sensitivity analysis was done to test the robustness of analyses by reanalyzing all continuous data with a random-effects model instead of a fixed-effect model. The results of the analysis did not change considerably by changing the effects model. However, the results differed depending on whether a weighted or standardized mean difference was used (analysis of relative change in motor function until final follow up).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-16 10:48:43 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-07-16 10:48:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ten trials, with a total of 287 patients, were included. Three of the trials, including 111 patients, have been added to the first version of the review. Summary details of the trials are given in the 'Characteristics of included studies' table and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Thirteen studies were excluded for a variety of reasons (<I>see</I> 'Characteristics of excluded studies' table). No study is currently awaiting assessment. Several studies are ongoing (<I>see</I> 'Characteristics of ongoing studies' table).</P>
<SUBSECTION>
<HEADING LEVEL="3">Age and gender</HEADING>
<P>The mean age of patients in the included studies was 66 years and ranged from 31 to 91 years. The mean age is based on all studies except <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK> where no information was given in the abstract. Most trials included more males than females.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Imaging</HEADING>
<P>CT (computed tomography) or MRI (magnetic resonance imaging) of the head was performed in all studies, including 287 patients. All but two studies, including 111 patients, (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>) included only patients with ischaemic stroke. One study (including 45 patients) enrolled patients within 72 hours after stroke onset (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>), four studies (including 146 patients) within 10 days (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>), two studies (including 31 patients) within 30 days (<LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>), two studies (including 45 patients) within 45 days (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>, <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>), and one study (including 26 patients) within six months (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Exclusion criteria</HEADING>
<P>Six studies, including 192 patients, excluded patients that were receiving drugs such as alpha-adrenergic antagonists or agonists, and tranquillizers (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Five studies, including 89 patients, excluded patients with hypertension according to pre-specified upper limits for systolic and diastolic blood pressure levels (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Six studies, including 214 patients, also excluded patients with various forms of heart disease (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time from stroke onset until treatment start</HEADING>
<P>One study, including 45 patients, started treatment within 72 hours from stroke onset (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). One study, including 27 patients, had a mean time from stroke onset until treatment start of five to six days (<LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>), and three studies, including 119 patients, included patients within the first 10 days (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>). Two studies, including 31 patients, included patients between 16 and 30 days after stroke onset (<LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). One study, including 26 patients, had a treatment start between three weeks and six months after stroke onset (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>). One study, including 24 patients, started treatment within the first six weeks (<LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>), and one study, including 21 patients, after the first month after stroke onset (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>).
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amphetamine schedule</HEADING>
<P>The scheduled period of amphetamine treatment in the included trials was one day in one study including eight patients (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>), five days in one study including 45 patients (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>), seven days in one study including 27 patients (<LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>), 17 days in one study including 21 patients (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>), three weeks in one study including 26 patients (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>), and approximately five weeks in five studies including 166 patients (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). In one of the studies including 45 patients amphetamine was administered twice daily (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). In the other three studies including 56 patients, with a treatment length of between one and 17 days, the dose was given once daily (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>). One study, including 26 patients, administered amphetamine twice per week (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>), while it was scheduled once daily every three to four days in the five studies including 166 patients, with a five-week period of treatment (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amphetamines</HEADING>
<P>The most common type of amphetamine administered was dexamphetamine, administered in eight studies including 226 patients (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Methamphetamine was used in one study including 27 patients (<LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>), and d,l-amphetamine in one study including 40 patients (<LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dosing</HEADING>
<P>The most common dose of amphetamine was 10 mg, administered in eight studies including 227 patients (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>), all but <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK> administrating d,l amphetamine, and <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK> used dexamphetamine. In one study, including 45 patients, doses of between 2.5 mg and 10 mg dexamphetamine twice daily were used (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>), and in one study including 21 patients (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>) doses started at 10 mg and then lowered to 5 mg in the last days of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time from amphetamine administration until training</HEADING>
<P>Two studies, including 31 patients, (<LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>) started the rehabilitation session 30 minutes after drug administration. Two studies, including 64 patients, (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>) started after 60 minutes. In one study, including 71 patients, rehabilitation started after 90 minutes (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>), and in one study including eight patients, rehabilitation was started within 180 minutes (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>). In one study, including 27 patients, the time from amphetamine administration until start of rehabilitation was not specified in the protocol (<LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>). Two studies, including 66 patients, did not prespecify the time in the study protocol (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Concomitant rehabilitation</HEADING>
<P>Eight studies, including 227 patients, combined amphetamine administration in time with specific therapy (physiotherapy or speech therapy) according to a strict protocol (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>;<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>), while two studies, including 66 patients, did not purposely combine amphetamine administration with rehabilitation but all patients received standard rehabilitation (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time spent training </HEADING>
<P>The time spent training in each session varied between 30 minutes (<LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>) until 60 minutes (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). In two studies training lasted approximately 45 minutes (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>). In two studies patients had 'standard rehabilitation' at the present stay, stroke unit in the acute stage (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>) and inpatient rehabilitation (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>). In two studies time spent training is unknown (<LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>). The total number of sessions varied between one (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>) and 17 (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>). In one study, the number of sessions was five (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>), six sessions in one study (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>), seven in one study (<LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>), 10 in five studies (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>), and 17 in one study (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Follow-up period</HEADING>
<P>The duration of follow up varied between one day in one study including eight patients (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>) after drug discontinuation to 12 months post stroke in three studies including 60 patients (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of outcome</HEADING>
<P>The most common outcome measure used in studies was motor function, which was assessed in all studies except one including 21 patients (<LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). The Fugl-Meyer motor scale was used in the majority of the studies but two studies, including 50 patients, used other outcome measures (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>). Activities of daily living were assessed in four studies including 130 patients (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>), neurological function in one study including 45 patients (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>), language recovery in one study including 21 patients (<LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>), and depression in one study including 21 patients (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>). One study including 45 patients reported mortality and any adverse event as primary safety outcomes (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). Two more studies, including 97 patients, collected information about adverse events systematically (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>). In the other six studies including 127 patients, systematic collection of adverse events were pre-specified in the study protocol (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Three studies including 156 patients had cases with fatal outcomes (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>), while the seven other studies, including 137 patients, were free of deaths (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>).</P>
<P>Assessments of health-related quality of life or cognitive function were not undertaken in any of the trials.</P>
<P>Three studies including 39 patients reported that heart rate and blood pressure were measured but these data were not published or provided upon request (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Data from two of these studies including 31 patients (<LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>) are published as part of another study (<LINK REF="STD-Unwin-2000" TYPE="STUDY">Unwin 2000</LINK>) in 46 patients (the total number of patients included in the Walker-Batson studies was 31) but it was not possible to identify which patients were included in each of the two studies (<LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Blood pressure and heart rate data are not available for one of the studies including eight patients (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>). Thus, only two studies including 71 patients (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>) with reported blood pressure and heart rate data were used in the review.</P>
<P>Adverse events were recorded specifically in three studies including 142 patients (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-16 10:34:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>Generally, the quality of the included trials is high but there are studies with patients lost to follow up with missing data. If published information about the study quality could not be found, we contacted study authors for more information.</P>
<SUBSECTION>
<HEADING LEVEL="3">Randomization</HEADING>
<P>Of the ten trials, eight had Grade A level of adequate concealment of randomization (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>;<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK> ;<LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Two studies reported some details in the original paper of the methods of randomization but, despite further information being provided by the authors, the exact procedures were still unclear and the studies were graded as level B, uncertain concealment of randomization (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Baseline comparison of experimental groups</HEADING>
<P>All 10 trials compared the experimental groups at baseline. Four studies (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>) reported statistically significant imbalances in important baseline prognostic variables, although the small size of the other studies does not rule out that this may have been a problem elsewhere.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Explicit diagnostic criteria</HEADING>
<P>All 10 trials reported explicit diagnostic criteria for patients included in the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Eight trials were double blind (that is, patient and all investigators were unaware of treatment allocation) (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>), and two trials were single blind (that is, patients and outcome assessors were not aware of treatment allocation, some investigators knew the treatment allocation, but were not involved in the treatment or assessment of the patients) (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Losses to follow up</HEADING>
<P>Generally, losses of patients were well described but in several studies (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>) the patients were not followed according to the intention to treat principle (<LINK REF="REF-Montori-2001" TYPE="REFERENCE">Montori 2001</LINK>).<B> </B>In total, 24 patients (8.4% of all patients randomized to any of the included studies) were reported as excluded from analyses after randomization because they were lost to follow up or for other reasons.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-16 10:35:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>In the pooled analysis, the number of patients is sometimes lower than the number of patients listed in the text due to patients being excluded after randomization because of death or because they were lost to follow up. Those lost to follow up were not included in an intention-to-treat analysis. To create uniformity in the figures of the plots, 'favours treatment' is always to the left, the 'treatment' and 'control' are not always placed in the same column (i.e. left or right).</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.01: Dead or dependent at final follow up</HEADING>
<P>Three trials with data from 106 patients (36.9% of all patients included in the overall review) reported death and disability in a way that allowed analysis (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>). Two studies had a final follow up of three months post stroke (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>), and one study at 12 months after inclusion to the study (<LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>). All three studies used the Barthel ADL Index for the measurement of dependency (<LINK REF="REF-Mahoney-1965" TYPE="REFERENCE">Mahoney 1965</LINK>). Treatment with amphetamines was not associated with a significant decrease of patients dead or dependent at final follow up, although the confidence interval was wide and included potentially clinically important effects in both directions (Peto OR 1.5; 95% CI 0.6 to 3.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.02: Death from all causes at final follow up</HEADING>
<P>Data were available for all 10 trials including 287 patients. In three studies involving 151 patients there were cases with a fatal outcome (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>). Treatment with amphetamines was associated with a non-significant increase in death at final follow up (Peto OR 2.8; 95% CI 0.9 to 8.6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.03: Death from all causes after end of treatment</HEADING>
<P>Data were available for all 10 trials including 287 patients. One of the seven studies (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>) reported cases of death during the treatment period. Amphetamines were associated with a non-significant increase in death at the end of treatment (Peto OR 5.7; 95% CI 0.7 to 45.6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Three trials, with data from 143 patients (49.8% of all patients included in the overall review), reported adverse events (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>). The adverse events during the treatment period are listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Blood pressure and heart rate were analysed separately. One other trial including data from 39 patients (13.6% of all patients included in the overall review) reported one adverse event from placebo (<LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>), while the other six studies including data from 110 patients (38.3% of all patients included in the overall review) reported no adverse events (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>; <LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparisons 01.04, 01.06, 01.08: Blood pressure and heart rate during treatment</HEADING>
<P>Data on these variables were available from two trials with a total of 71 patients (24.7% of all patients included in the overall review) (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>). Systolic blood pressure was significantly higher during the intervention period in amphetamine-treated patients compared to placebo-treated patients (WMD 8.4; 95% CI 1.6 to 15.2). A similar effect was seen for diastolic blood pressure (WMD 4.9; 95% CI 1.1 to 8.8) and heart rate that increased significantly with amphetamine treatment (WMD 10.6; 95% CI 3.3 to 17.8). Heterogeneity was observed in the analysis of heart rate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparisons 01.05, 01.07, 01.09: Change in blood pressure and heart rate during treatment</HEADING>
<P>Data for these variables were available from one trial with 45 patients (15.7% of all patients included in the overall review) (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). Systolic and diastolic blood pressure did not decrease to the same extent in the amphetamine group as in the placebo-treated group during the first week after stroke onset (WMD 13.6; 95% CI 5.2 to 22.1 and WMD 7.6; 95% CI 2.5 to 12.8 respectively). Heart rate increased significantly with amphetamine treatment (WMD 9.0; 95% CI 3.6 to 14.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.10: Motor function at final follow up</HEADING>
<P>Eight trials with data from 226 patients (78.7% of all patients included in the overall review) reported assessment of motor function. Six of the trials, including 171 patients, (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Vachalathiti-2001" TYPE="STUDY">Vachalathiti 2001</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>) used the Fugl-Meyer motor scale (FM) (<LINK REF="REF-Fugl_x002d_Meyer-1977" TYPE="REFERENCE">Fugl-Meyer 1977</LINK>). One trial including 45 patients (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>) used the Lindmark motor assessment chart (LMAC) (<LINK REF="REF-Lindmark-1988a" TYPE="REFERENCE">Lindmark 1988a</LINK>; <LINK REF="REF-Lindmark-1988b" TYPE="REFERENCE">Lindmark 1988b</LINK>). Since the FM score and the LMAC score are highly correlated (<LINK REF="REF-Lindmark-1988a" TYPE="REFERENCE">Lindmark 1988a</LINK>), the LMAC score for the paretic side was transformed to the FM score. One trial including 26 patients (<LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>) used the Rivermead Motor Assessment Score (RMA) (<LINK REF="REF-Collen-1990" TYPE="REFERENCE">Collen 1990</LINK>). The 'arm' and 'leg and trunk' RMA score was used in the analysis, while the 'gross function' was left out because it differs in content compared to the FM. In one trial, with a final follow up of 12 months, only data from 2.5 months could be used (<LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>). Overall, treatment with amphetamines was not associated with a significant improvement in motor function at follow up (SMD -0.1; 95% CI -0.3 to 0.2). The intention-to-treat analysis, based on seven trials including 174 patients (60.6% of all patients included in the overall review), showed a result in the same direction (SMD 0; 95% CI -0.4 to 0.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.11: Relative change in motor function until final follow up</HEADING>
<P>Six studies with data from 176 patients (61.3% of all patients included in the overall review) provided data for the analysis (<LINK REF="STD-Crisostomo-1988" TYPE="STUDY">Crisostomo 1988</LINK>; <LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>; <LINK REF="STD-Walker_x002d_Batson-1995" TYPE="STUDY">Walker-Batson 1995</LINK>). Treatment with amphetamines was associated with a significantly better motor recovery from baseline to final follow up (WMD -6.1; 95% CI -10.4 to -1.9). The intention-to-treat analysis, based on five studies including 126 patients (43.9% included in the overall review), showed a result in the same direction (WMD -7.8; 95% CI -13.3 to -2.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.12: Time to complete motor task</HEADING>
<P>One study (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>) with data from 26 patients (9.1% of all patients included in the overall review) measured the upper extremity motor function with a timed test (<LINK REF="REF-Desrosiers-1993" TYPE="REFERENCE">Desrosiers 1993</LINK>) that is not comparable to the ordinal scales used in the other studies. The data from this study were therefore analysed separately. Treatment with amphetamines was not associated with a possibility of moving the upper extremity faster (WMD -2.7; 95% CI -13.6 to 8.2) although the confidence interval does not rule out a treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.13: Time to walk 10 metres</HEADING>
<P>One study with data from 17 patients (9.1% of all patients included in the overall review) contributed data to the analysis (<LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>). Treatment with amphetamines was not associated with an ability to walk 10 metres faster (WMD -0.6; 95% CI -2.9 to 1.6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.14: Activities of daily living at final follow up</HEADING>
<P>Four studies with 113 patients (39.4 % of all patients included in the overall review) were included (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>). They all used the Barthel Index (<LINK REF="REF-Mahoney-1965" TYPE="REFERENCE">Mahoney 1965</LINK>). Amphetamine treatment was not associated with a statistically significant improvement in ADL function at follow up (WMD 3.9; 95% CI -5.8 to 13.5). The intention-to-treat analysis, based on 129 patients (44.9% of all patients included in the overall review), showed an almost significant benefit of placebo compared to amphetamine treatment with the lower confidence interval close to unity (WMD 9.9; 95% CI -0.3 to 20.0).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.15: Relative change in activities of daily living until final follow up</HEADING>
<P>Three studies with 92 patients were included in this analysis (32.1 % of all patients included in the overall review) (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>; <LINK REF="STD-Treig-2003" TYPE="STUDY">Treig 2003</LINK>). Amphetamine treatment was not associated with a statistically significant improvement in ADL function at follow up (WMD -0.3; 95% CI -9.3 to 8.8). The intention-to-treat analysis, based on 108 patients (37.6% of all patients included in the overall review), showed a result in the same direction (WMD 8.1; 95% CI -4.0 to 20.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.16: Neurological function at final follow up</HEADING>
<P>One study with 34 patients (11.8 % of all patients included in the overall review) was included in the analysis (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). Neurological function was assessed with the Scandinavian Stroke Scale (<LINK REF="REF-Scandinavian-1985" TYPE="REFERENCE">Scandinavian 1985</LINK>). Amphetamine treatment was not associated with a statistically significant improvement in neurological function at follow up (WMD -4.0; 95% CI -14.9 to 7.0). Neither was an association seen in the intention-to-treat analysis, based on 45 patients (15.7% of all patients included in the overall review) (WMD 5.8; 95% CI -8.6 to 20.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.17: Relative change in neurological function until final follow up</HEADING>
<P>The same data as described in 'Neurological function at final follow up' were available for this analysis. Amphetamine treatment was not associated with a statistically significant improvement in neurological function at follow up (WMD -3.7; 95% CI -11.6 to 4.3). Neither was an association seen in the intention-to-treat analysis (WMD 18.6; 95% CI -11.1 to 48.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.18: Language function at final follow up</HEADING>
<P>One study with 20 patients (7.0% of all patients included in the overall review) was included in this analysis (<LINK REF="STD-Walker_x002d_Batson-2001" TYPE="STUDY">Walker-Batson 2001</LINK>). Language function was assessed with the Porch Index of Communicative Ability (PICA) (<LINK REF="REF-Porch-1982" TYPE="REFERENCE">Porch 1982</LINK>). Amphetamine treatment was not associated with a statistically significant improvement in language function at follow up (WMD -4.2; 95% CI -22.0 to 13.6). The intention-to-treat analysis, based on 21 patients (7.3% of all patients included in the overall review) showed a result in the same direction (WMD -5.3; 95% CI -22.6 to 11.9).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.19: Change in language function until final follow up</HEADING>
<P>The same data, as described in 'Language function at final follow up' were available for this analysis. Amphetamine was associated with better language function at follow up (WMD -7.5; 95% CI -14.4 to -0.6). The intention-to-treat analysis showed a result in the same direction (WMD -7.4; 95% CI -14.1 to -0.7).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01.20: Depression at final follow up</HEADING>
<P>One study with data from 21 patients (7.3% of all patients included in the overall review) was available for the analysis (<LINK REF="STD-Reding-1995" TYPE="STUDY">Reding 1995</LINK>). Depression grade was assessed with the Zung Self-rating Depression Scale (<LINK REF="REF-Zung-1965" TYPE="REFERENCE">Zung 1965</LINK>). Amphetamine was not associated with a statistically significant reduction in depression grade at follow up (WMD -2.0; 95% CI -10.3 to 6.3).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Treatments for acute stroke should aim to improve recovery as well as survival. The present evidence from randomized controlled trials does not indicate that treatment with amphetamine reduces the combined outcome of death or disability. Rather, there is an indication that there might be an increased risk of death from amphetamines. The results should however be interpreted with caution since there were statistically significant baseline differences in characteristics for important prognostic variables in studies reporting deaths. For instance, the mean age was significantly higher (five years) (<LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>), the level of consciousness significantly lower (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>), and the number of patients living alone prior to the stroke significantly higher (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>) in amphetamine-allocated patients, which could have biased the results. Moreover, these results are based on only three studies and therefore prone to random error and wide uncertainty around the point estimate (<LINK REF="STD-Gladstone-2006" TYPE="STUDY">Gladstone 2006</LINK>; <LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Sonde-2001" TYPE="STUDY">Sonde 2001</LINK>).</P>
<P>A wide range of outcome variables were evaluated in the review, such as blood pressure and heart rate, motor function including time to complete a task and walk 10 metres, ADL, neurological function, language function, and depression grade. It is important to notice that with more outcomes evaluated, the risk of finding associations that may be attributed to chance alone increases. Systolic and diastolic blood pressure and heart rate increased significantly with amphetamine treatment as seen in analyses of both raw and difference data. The reduction of blood pressure levels and heart rate was slower in amphetamine-treated patients compared with those on placebo during the first week after stroke onset as analysed by the mean differences with data from one study (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). An increase in blood pressure is common, but it usually decreases during the next week after stroke onset (<LINK REF="REF-Bath-1997" TYPE="REFERENCE">Bath 1997</LINK>). The effects of delaying a natural decrease of blood pressure with amphetamines are unknown. Also, the trial contributing data to this analysis was performed in patients early after stroke onset. In the analysis of heart rate the test for heterogeneity was statistically significant, while it was not significant for either systolic or diastolic blood pressure. Patients in the two studies contributing data to the analysis differed in inclusion time from stroke onset, dosing regimen, rehabilitation schedule, and time point for measurements after amphetamine administration (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>; <LINK REF="STD-Platz-2005" TYPE="STUDY">Platz 2005</LINK>). These differences might explain the heterogeneity.<BR/> <BR/>The present evidence from randomized controlled trials does not indicate a statistically significant benefit of amphetamine treatment regarding ADL, neurological function or depression grade, but suggests that motor and language function may improve with amphetamine treatments as assessed by a relative change in scores, from baseline to end of follow up. However, when the raw data at follow up were analysed, there was no difference in the measures between groups. These differences in the separate analyses might be explained by (1) baseline differences favouring the placebo-treated group when analysing raw data, and (2) exclusion of data not possible to transform, as eight studies were included in the analysis of raw data compared with six studies in the analysis of transformed data (relative change data). Moreover, the two studies that could not be included in the latter analysis had a mean score favouring control treatment, although the confidence intervals do not rule out a treatment effect. Analysis of the raw data and transformed ADL data showed no benefit of the treatment while the intention-to-treat analysis for both the raw data and the transformed data showed a borderline significant difference in favour of placebo. Only one study reported effects on language outcome. Analysis of the raw data showed no evidence of benefit while an analysis of the transformed score shows evidence of benefit from amphetamines. The different results from the analyses further emphasize caution in the interpretation of the results.</P>
<P>The intention-to-treat analysis was statistically significant in favour of amphetamine, that is, as in the same direction for motor function and relative change of motor function in the analysis based on surviving patients. The trend in favour of placebo in ADL outcome in the analysis of surviving patients was borderline significant in the intention-to-treat analysis. For neurological function the very weak trend in favour of amphetamine treatment changed to a very weak trend in favour of control treatment in the intention-to-treat analysis. The differences between the intention-to-treat analyses and the analyses based on only surviving patients were related to the higher proportion of patients who died in the amphetamine-treated group.</P>
<P>The evaluation of subgroups, particularly when only small numbers of patients and outcomes are evaluated, is prone to error. Therefore, we did not perform subgroup analysis for the effect of differences in the time from onset of stroke to treatment, dosage, different types of amphetamine, treatment duration, combination with rehabilitation, different types of rehabilitation, duration of rehabilitation, different origin of stroke (i.e. ischaemic and haemorrhagic), or stroke severity. All these parameters are possible confounders of the efficacy of amphetamine treatment.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no evidence to suggest that amphetamine treatment after stroke reduces the combined outcome of death or dependence. Evidence from this systematic review indicates that amphetamine might increase the risk of death and shows evidence that amphetamine increases blood pressure levels and heart rate and slows down the natural reduction in elevated blood pressure seen during the first week after stroke onset. However, these data show the benefit of treatment on motor and language function although the results should be interpreted with caution as different approaches to the analysis gave different results. The data do not provide evidence that amphetamine treatment improves activities of daily living, neurological function, or depression. Based on the present evidence, there is no indication for the routine use of amphetamines to improve recovery after stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The number of patients included in studies to date is too small to draw firm conclusions regarding the effect of amphetamines on the recovery from stroke. Further research in this area is therefore justified. Further trials, balanced for important prognostic factors, evaluating the long-term effects (at least 12 months) of amphetamine on substantive outcomes and a broad range of outcome variables, are needed to influence clinical practice. Data in future trials should be collected in such a way that the key outcomes are compatible with the basic outcome assessments as outlined in this review (e.g. death, death and dependence (preferably assessed with the Barthel Index), adverse events, blood pressure and heart rate, and motor function (preferably assessed with the Fugl-Meyer motor score)).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank the following individual trialists for supplying additional information about studies: Prof S Hesse, Dr D Gladstone, Dr T Platz, Dr M Reding, Dr L Sonde, Dr R Vachalathiti, Dr D Walker-Batson and the late Prof J Davis. Dr W Ziegler is acknowledged for providing unpublished data and Prof A Shuaib for trying to find data from a study performed many years ago, Prof P Bath, Prof L Cohen, Prof L Goldstein and Dr M Wilmot for providing information about ongoing trials; H Fraser for her willingness to answer all our questions related to the review; B Thomas for helping us with the search strategies. </P>
<P>Prof Nils Gunnar Wahlgren is acknowledged for his contribution as a co-author of the first version of the review. For help with the first version of the review we also acknowledge H Fraser and S Dixon for supplying regular lists of trials identified in the Cochrane Stroke Group's Trials Register, Dr S Lewis for giving statistical advice, N Ahmed for solving controversies between review authors, and Dr S Eksborg for valuable comments on the manuscript. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Dr Louise Martinsson and Prof Nils Gunnar Wahlgren (co-author of the first version of the review) have been involved in one trial included in the review (<LINK REF="STD-Martinsson-2003" TYPE="STUDY">Martinsson 2003</LINK>). Dr Hans-Göran Hårdemark was chairman of the safety committee in the same study. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Louise Martinsson: conceived, designed and co-ordinated the review; entered and collected data, and was responsible for data management; undertook searches, analysis and interpretation of the data; and wrote the review.</P>
<P>Staffan Eksborg: undertook interpretation of the data, and wrote the review.</P>
<P>Hans-Göran Hårdemark: undertook searches, interpretation of the data, and wrote the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-16 10:40:32 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Crisostomo-1988" NAME="Crisostomo 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN</AU>
<TI>Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients</TI>
<SO>Annals of Neurology</SO>
<YR>1988</YR>
<VL>23</VL>
<PG>94-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gladstone-2006" NAME="Gladstone 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines WR, Graham SJ, et al</AU>
<TI>Physiotherapy coupled with dextroamphetamine for motor rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Stroke</SO>
<YR>2006</YR>
<VL>37</VL>
<PG>179-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Martinsson-2003" NAME="Martinsson 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martinsson L, Wahlgren NG</AU>
<TI>Safety of dexamphetamine in acute ischemic stroke: a randomized double-blind, controlled dose-escalation trial</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>475-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Platz-2005" NAME="Platz 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Platz T, Kim I-H, Engel U, Pinkowski C, Eickhof C, Kutzner M</AU>
<TI>Amphetamine fails to facilitate motor performance and to enhance motor recovery among stroke patients with mild arm paresis: interim analysis and termination of a double blind, randomised, placebo-controlled trial</TI>
<SO>Restorative Neurology and Neuroscience</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>271-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Reding-1995" NAME="Reding 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borucki SJ, Langberg J, Reding M</AU>
<TI>The effect of dextroamphetamine on motor recovery after stroke [Abstract]</TI>
<SO>Neurology</SO>
<YR>1992</YR>
<VL>42 (Suppl 3)</VL>
<PG>329</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Secondary reference: Borucki SJ, Langberg J, Reding M. The effect of dextroamphetamine on motor recovery after stroke. Neurology 1992;42 (Suppl 3):329.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reding MJ, Solomon B, Borucki S</AU>
<TI>Effect of dextroamphetamine on motor recovery after stroke [Abstract]</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45 (Suppl 4)</VL>
<PG>S01</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sonde-2001" NAME="Sonde 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sonde L, Nordström M, Nilsson C-G, Lökk J</AU>
<TI>A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>253-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Treig-2003" NAME="Treig 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Treig T, Werner C, Sachse M, Hesse S</AU>
<TI>No benefit from D-amphetamine when added to physiotherapy after stroke: a randomized, placebo-controlled study</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>590-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Vachalathiti-2001" NAME="Vachalathiti 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vachalathiti R, Asavavallobh C, Nilanont Y, Poungvarin N</AU>
<TI>Comparison of physical therapy and physical therapy with amphetamine in sensorimotor recovery of acute stroke patients: randomized controlled trial [Abstract]</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>187 (Suppl 1)</VL>
<PG>S253</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Walker_x002d_Batson-1995" NAME="Walker-Batson 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R</AU>
<TI>Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence</TI>
<SO>Stroke</SO>
<YR>1995</YR>
<VL>26</VL>
<PG>2254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker_x002d_Batson-2001" NAME="Walker-Batson 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, et al</AU>
<TI>A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>2093-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Benson-1970" NAME="Benson 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Benson DF</AU>
<SO>Presentation 10 - Aphasia therapy</SO>
<YR>1970</YR>
<PG>77</PG>
<ED>Benton AL</ED>
<PB>Harper &amp; Row</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mazagri-1995" NAME="Mazagri 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mazagri R, Shuaib A, McPherson M, Deighton M</AU>
<TI>Amphetamine failed to improve motor function in acute stroke [Abstract]</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>S25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McNeil-1997" NAME="McNeil 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McNeil MR, Doyle PJ, Spencer KA, Jackson Goda A, Flores D, Small SL</AU>
<TI>A double-blind, placebo-controlled study of pharmacological and behavioral treatment of lexical-semantic deficits in aphasia</TI>
<SO>Aphasiology</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>385-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niklasson-1992" NAME="Niklasson 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Niklasson B</AU>
<TI>Recovery of motor function after stroke: balance agnosia and amphetamine [Abstract]</TI>
<SO>European Journal of Neuroscience</SO>
<YR>1992</YR>
<VL>173(Suppl 5)</VL>
<PG>212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unwin-2000" NAME="Unwin 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Unwin H, Walker-Batson D</AU>
<TI>No side effects after low-dose amphetamine administration in stroke rehabilitation</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>1788-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Volpe-2000" NAME="Volpe 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volpe BT, Shelton F, Krebs HI, Hogan N, Diels C, Reding M</AU>
<TI>Dextroamphetamine paired with standard and robotic neurorehabilitation changes motor performance one day later</TI>
<SO>Annals of Neurology</SO>
<YR>2000</YR>
<VL>48</VL>
<PG>454</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker_x002d_Batson-1992" NAME="Walker-Batson 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Batson D, Unwin H, Curtis S, Allen E, Wood M, Smith P, et al</AU>
<TI>Use of amphetamine in the treatment of aphasia</TI>
<SO>Restorative Neurology and Neuroscience</SO>
<YR>1992</YR>
<VL>4</VL>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker_x002d_Batson-1996" NAME="Walker-Batson 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Batson D, Curtis S, Wolf T, Porch B</AU>
<TI>Administration of amphetamine accelerates recovery from aphasia</TI>
<SO>Brain and Language</SO>
<YR>1996</YR>
<VL>55</VL>
<PG>27-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Widdig-2003" NAME="Widdig 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Widdig W, Pleger B, Rommel O, Malin J-P, Tegenthoff M</AU>
<TI>Repetitive visual stimulation: a neuropsychological approach to the treatment of cortical blindness</TI>
<SO>NeuroRehabilitation</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>227-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wongjitrat-1996" NAME="Wongjitrat 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wongjitrat C, Vachalathiti R, Chaisevikul R, Poungvarin N</AU>
<TI>The pilot study of the effect of physical therapy with amphetamine in sensorimotor recovery of acute stroke patients</TI>
<SO>Siriraj Hospital Gazette</SO>
<YR>1996</YR>
<VL>48</VL>
<PG>577-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziegler-1993" NAME="Ziegler 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Secondary reference: M&amp;#252;ller U, Ziegler W, von Cramon DY. Amphetamine in apraxia of speech. Neuropsychopharmacology 1994;10:226S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Müller U, Ziegler W, von Cramon DY</AU>
<TI>Amphetamine in apraxia of speech [Abstract]</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>226S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Ziegler W, Müller U</AU>
<TI>Amphetamine in apraxia of speech</TI>
<SO>International Congress on Stroke Rehabilitation</SO>
<YR>1993</YR>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Bath" NAME="Bath" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Bath P</AU>
<TI>Stroke trial of amphetamine and recovery</TI>
<SO>Personal correspondence</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Cohen" NAME="Cohen" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Cohen L</AU>
<TI>Improvement of use dependent plasticity in chronic stroke patients</TI>
<SO>http://clinicalstudies.info.nih.gov/</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Goldstein" NAME="Goldstein" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Goldstein LB, Lennihan L, Rabadi M, Good DC, Dromerick AW, Hodics TM</AU>
<TI>The amphetamine-enhanced stroke recovery (AESR) trial [Abstract]</TI>
<SO>Proceedings of the International Stroke Conference 2005. Ongoing Clinical Trials Abstracts (Abst. CTP51)</SO>
<YR>2005</YR>
<PB>American Stroke Association</PB>
<CY>New Orleans, Louisiana</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-16 10:40:32 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-16 10:40:32 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Adkins-2005" NAME="Adkins 2005" TYPE="JOURNAL_ARTICLE">
<AU>Adkins DL, Jones TA</AU>
<TI>D-amphetamine enhances skilled reaching after ischemic cortical lesions in rats</TI>
<SO>Neuroscience Letters</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1989" NAME="Bamford 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bamford KM, Sandercock PAG, Warlow C, Slattery J</AU>
<TI>Interobserver agreement for the assessment of handicap in stroke patients</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>828</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-1997" NAME="Bath 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bath FJ, Bath PMW</AU>
<TI>What is the correct management of blood pressure in acute stroke? The Blood Pressure in Acute Stroke Collaboration</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>205-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonita-1992" NAME="Bonita 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bonita R</AU>
<TI>Epidemiology of stroke</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<PG>342-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boyeson-1991" NAME="Boyeson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Boyeson MG, Feeney DM</AU>
<TI>Adverse effects of cateholaminergic drugs following unilateral lesions</TI>
<SO>Restorative Neurology and Neuroscience</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>227-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2004" NAME="Brown 2004" TYPE="JOURNAL_ARTICLE">
<AU>Brown AW, Bjelke B, Fuxe K</AU>
<TI>Motor response to amphetamine treatment, task-specific training, and limited motor experience in a postacute animal stroke model</TI>
<SO>Experimental Neurology</SO>
<YR>2004</YR>
<VL>190</VL>
<PG>102-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collen-1990" NAME="Collen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Collen FM, Wade DT, Bradshaw CM</AU>
<TI>Mobility after stroke: reliability of measures of impairment and disability</TI>
<SO>International Disability Studies</SO>
<YR>1990</YR>
<VL>12</VL>
<PG>6-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Desrosiers-1993" NAME="Desrosiers 1993" TYPE="JOURNAL_ARTICLE">
<AU>Desrosiers J, Hebert R, Dutil E, Bravo G</AU>
<TI>Development and reliability of an upper extremity function test for the elderly: The TEMPA</TI>
<SO>Canadian Journal of Occupational Therapy</SO>
<YR>1993</YR>
<VL>60</VL>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feeney-1982" NAME="Feeney 1982" TYPE="JOURNAL_ARTICLE">
<AU>Feeney DM, Gonzales A, Law WA</AU>
<TI>Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury</TI>
<SO>Science</SO>
<YR>1982</YR>
<VL>217</VL>
<PG>855-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feeney-1988" NAME="Feeney 1988" TYPE="BOOK_SECTION">
<AU>Feeney D, Sutton R</AU>
<TI>Cateholamines and recovery of function after brain damage</TI>
<SO>Pharmacological approaches to the treatment of brain and spinal cord injury</SO>
<YR>1988</YR>
<PG>121-42</PG>
<ED>Stien D, Sabel B</ED>
<PB>Plenum Publishing Corporation</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feeney-1998a" NAME="Feeney 1998a" TYPE="BOOK_SECTION">
<AU>Feeney DM</AU>
<TI>Rehabilitation pharmacology: noradrenergic enhancement of physical therapy</TI>
<SO>Cerebrovacular Diseases</SO>
<YR>1998</YR>
<ED>Ginsberg M, Bogousslavsky J</ED>
<PB>Blackwell Science Publishing Company</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feeney-1998b" NAME="Feeney 1998b" TYPE="BOOK_SECTION">
<AU>Feeney DM</AU>
<TI>Noradrenergic modulation of physical therapy: effects on functional recovery after cortical injury</TI>
<SO>Restorative neurology. Advances in pharmacotherapy for recovery after stroke</SO>
<YR>1998</YR>
<PG>39-40</PG>
<ED>Goldstein L</ED>
<PB>Futura Publishing Company Inc</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fugl_x002d_Meyer-1977" NAME="Fugl-Meyer 1977" TYPE="JOURNAL_ARTICLE">
<AU>Fugl-Meyer AR, Jääskö L, Leyman I, Olsson S, Steglind S</AU>
<TI>The post-stroke hemiplegic patient. A method for evaluation of physical performance</TI>
<SO>Scandinavian Journal of Rehabilitation Medicine</SO>
<YR>1975</YR>
<VL>7</VL>
<PG>13-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelmers-1988" NAME="Gelmers 1988" TYPE="JOURNAL_ARTICLE">
<AU>Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJ</AU>
<TI>A controlled trial of nimodipine in acute ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilmour-2005" NAME="Gilmour 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gilmour G, Iversen SD, O'Neill MF, O'Neill MJ, Ward MA, Bannerman DM</AU>
<TI>Amphetamine promotes task-dependent recovery following focal cortical ischaemic lesions in the rat</TI>
<SO>Behavioural Brain Research</SO>
<YR>2005</YR>
<VL>165</VL>
<PG>98-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gladstone-2002" NAME="Gladstone 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gladstone DJ, Black SE, Hakim A for the Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery</AU>
<TI>Toward wisdom from failure. Lessons from neuroprotective stroke trials and new therapeutic directions</TI>
<SO>Stroke</SO>
<YR>2002</YR>
<VL>33</VL>
<PG>2123-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1990" NAME="Goldstein 1990" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein LB, Davis JN</AU>
<TI>Post-lesion and amphetamine-facilitated recovery of beam-walking in the rat</TI>
<SO>Restorative Neurology and Neuroscience</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>311-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1998" NAME="Goldstein 1998" TYPE="BOOK">
<AU>Goldstein LB</AU>
<SO>Advances in pharmacotherapy for recovery after stroke</SO>
<YR>1998</YR>
<PB>Futura Publishing Company Inc</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurwitz-1991" NAME="Hurwitz 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hurwitz BE, Dietrich WD, McCabe PM, Alonso O, Watson BD, Ginsberg MD, et al</AU>
<TI>Ampetamine promotes recovery from sensory-motor integration deficit after thrombotic infarction of the somatosensory rat cortex</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<PG>648-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kornetsky-1969" NAME="Kornetsky 1969" TYPE="JOURNAL_ARTICLE">
<AU>Kornetsky C</AU>
<TI>The pharmacology of the amphetamines</TI>
<SO>Seminars in Psychiatry</SO>
<YR>1969</YR>
<VL>1</VL>
<PG>227-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lees-2006" NAME="Lees 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lees KR, Zivin JA, Aschwood T, Davalos A, Davis SM, Diener H-C et al</AU>
<TI>NXY-059 for acute ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>588-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindmark-1988a" NAME="Lindmark 1988a" TYPE="JOURNAL_ARTICLE">
<AU>Lindmark B, Hamrin E</AU>
<TI>Evaluation of functional capacity after stroke as a basis for active intervention. Validation of a modified chart for motor capacity assessment</TI>
<SO>Scandinavian Journal of Rehabilitation Medicine</SO>
<YR>1988</YR>
<VL>20</VL>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindmark-1988b" NAME="Lindmark 1988b" TYPE="JOURNAL_ARTICLE">
<AU>Lindmark B, Hamrin E</AU>
<TI>Evaluation of functional capacity after stroke as a basis for active intervention. Presentation of a modified chart for motor chapacity assessment and its reliability</TI>
<SO>Scandinavian Journal of Rehabilitation Medicine</SO>
<YR>1988</YR>
<VL>20</VL>
<PG>103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mackay-2004" NAME="Mackay 2004" TYPE="OTHER">
<AU>Mackay J, Mensah GA</AU>
<TI>The atlas of heart disease and stroke</TI>
<SO>World Health Organization, Geneva.</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahoney-1965" NAME="Mahoney 1965" TYPE="JOURNAL_ARTICLE">
<AU>Mahoney FI, Barthel DW</AU>
<TI>Functional evaluation: The Barthel Index</TI>
<SO>Maryland State Medical Journal</SO>
<YR>1965</YR>
<VL>14</VL>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mintz-1986" NAME="Mintz 1986" TYPE="JOURNAL_ARTICLE">
<AU>Mintz M, Tomer R</AU>
<TI>Exposure to amphetamine after substantia nigra lesions interferes with the process of behavioral recovery</TI>
<SO>Pharmacology, Biochemistry and Behavior</SO>
<YR>1986</YR>
<VL>25</VL>
<PG>1307-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montori-2001" NAME="Montori 2001" TYPE="JOURNAL_ARTICLE">
<AU>Montori VM, Guyatt GH</AU>
<TI>Intention-to-treat principle</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2001</YR>
<VL>13</VL>
<PG>1339-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nudo-2003" NAME="Nudo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nudo RJ</AU>
<TI>Adaptive plasticity in motor cortex: implications for rehabilitation after brain injury</TI>
<SO>Journal of Rehabilitation Medicine</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1998" NAME="Petitti 1998" TYPE="JOURNAL_ARTICLE">
<AU>Petitti DB, Sidney S, Quesenberry C, Bernstein A</AU>
<TI>Stroke and cocaine or amphetamine use</TI>
<SO>Epidemiology</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>596-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porch-1982" NAME="Porch 1982" TYPE="BOOK">
<AU>Porch B</AU>
<SO>The Porch index of communicative abilities</SO>
<YR>1982</YR>
<PB>Consulting Psychologists Press</PB>
<CY>Palo Alto, California</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scandinavian-1985" NAME="Scandinavian 1985" TYPE="JOURNAL_ARTICLE">
<AU>Scandinavian Stroke Study Group</AU>
<TI>Multicenter trial of hemodilution in ischemic stroke - background and study protocol</TI>
<SO>Stroke</SO>
<YR>1985</YR>
<VL>16</VL>
<PG>855-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stroemer-1994" NAME="Stroemer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Stroemer RP, Kent TA, Hulsebosch CE</AU>
<TI>Amphetamine permanently promote recovery following cortical infarction</TI>
<SO>Society for Neuroscience Abstracts</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>186</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stroemer-1998" NAME="Stroemer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stroemer RP, Kent TA, Hulsebosch CE</AU>
<TI>Enhanced neocortical neural sprouting, synaptogenesis and behavioral recovery with d-amphetamine therapy after neocortical infarction in rats</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>2381-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stroke-Unit-2001" MODIFIED="2008-07-16 10:39:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="Stroke Unit 2001" TYPE="COCHRANE_REVIEW">
<AU>Stroke Unit Trialists' Collaboration</AU>
<TI>Organised inpatient (stroke unit) care for stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-07-16 10:39:26 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-07-16 10:39:26 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000197. DOI: 10.1002/14651858.CD000197.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sulter-1999" NAME="Sulter 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sulter G, Steen C, De Keyser J</AU>
<TI>Use of the Barthel Index and modified Rankin scale in acute stroke trials</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>1538-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wade-1992" NAME="Wade 1992" TYPE="JOURNAL_ARTICLE">
<AU>Wade DT</AU>
<TI>Stroke: rehabilitation and long-term care</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<PG>791-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2003" MODIFIED="2008-07-16 10:40:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wardlaw 2003" TYPE="COCHRANE_REVIEW">
<AU>Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E</AU>
<TI>Thrombolysis for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-07-16 10:40:32 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-07-16 10:40:32 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000213. DOI: 10.1002/14651858.CD000213"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1989" NAME="WHO 1989" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Recommendations on stroke prevention, diagnosis, and therapy</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>1407-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zung-1965" NAME="Zung 1965" TYPE="JOURNAL_ARTICLE">
<AU>Zung WWK</AU>
<TI>A self-rating depression scale</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1965</YR>
<VL>12</VL>
<PG>63-70</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Martinsson-2003b" NAME="Martinsson 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Martinsson L, Hårdemark H-G, Wahlgren NG</AU>
<TI>Amphetamines for improving stroke recovery: a systematic Cochrane review</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>2766</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Crisostomo-1988">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded<BR/>Randomisation procedure: an unblinded observer (not involved in treatment or outcome assessments) randomly assigned patients amphetamine or placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>8 patients<BR/>Age: range 47 to 73 years, mean 61 years<BR/>12% female<BR/>100% CT before entry<BR/>All cerebral infarction<BR/>Less than 10 days since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + physiotherapy vs placebo + physiotherapy<BR/>Physiotherapy: less than 45 minutes designed to facilitate active use of the affected limb(s)<BR/>Type of amphetamine: dexamphetamine (Dexidrine)<BR/>Dose of amphetamine: 10 mg<BR/>Duration: 1 day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function<BR/>Assessment scale: Fugl-Meyer motor scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 1 day after drug discontinuation (approximately 10 to 13 days after stroke onset)<BR/>Exclusions during trial: none<BR/>Loss to follow up: none<BR/>Excluded patients with hypertension or heart disease<BR/>No baseline imbalances reported<BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gladstone-2006">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded<BR/>Randomisation procedure: pre-numbered/coded identical containers, administered serially</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Canada<BR/>71 patients<BR/>Age: range 31 to 90 years, mean 68 years<BR/>46% female<BR/>100% CT or MRI before entry<BR/>Unilateral cerebral hemispheric stroke (infarct and haemorrhage)<BR/>5 to 10 days post stroke</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + physiotherapy vs placebo + physiotherapy<BR/>Amount and type of rehabilitation: physiotherapy (based on neurodevelopmental principles) 60 minutes after each administration<BR/>Type of amphetamine: dexamphetamine<BR/>Dose of amphetamine: 10 mg every 3 to 4 days<BR/>Duration: 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function including mobility/ambulation<BR/>Assessment scales: Fugl-Meyer motor scale, Functional Independence Measure, Chedoke-McMaster disability inventory, Clinical outcome variable scale, Chedoke-McMaster arm and hand activity inventory<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 3 months<BR/>Excluded patients with brainstem/cerebellar stroke, pre-existing deficit that could interfere with assessments, dementia, unstable angina, congestive heart failure, unstable arrhythmia or uncontrolled hypertension, psychosis, use of alpha-adrenergic antagonists/agonists or monoamine oxidase inhibitors, patients rapidly improving during the first week after stroke onset<BR/>Exclusions during trial: 4 patients (3 dexamphetamine, 1 placebo). 1 of the excluded dexamphetamine patients died during the intervention period Intention to treat: all patients not followed according to the intention-to-treat principle. 1 placebo patient received all 10 treatment sessions but died before the 3 month follow up. Data from this patient was included in the 6 week follow up but not at 3 months<BR/>Imbalances at baseline: the number of patients living alone were significantly lower in the placebo treated group <BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Martinsson-2003">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded<BR/>Randomisation procedure: centralised/pharmacy controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sweden<BR/>45 patients<BR/>Age: range 37 to 84 years, mean 67 years<BR/>42% female<BR/>100% CT before entry<BR/>All cerebral infarction<BR/>Less than 72 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine vs placebo<BR/>Amount and type of rehabilitation: standard treatment at a stroke unit at a acute care hospital<BR/>Type of amphetamine: Dexamphetamine<BR/>Dose of amphetamine: 5 to 20 mg/day (2.5 mg x 2 or 5 mg x 2 or 10 mg x 2)<BR/>Duration: 5 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events including mortality, blood pressure, heart rate, body temperature, level of consciousness<BR/>Efficacy (motor function, neurological function, ADL)<BR/>Assessment scales: Scandinavian Stroke Scale, Lindmark Motor Assessment Chart, Activity Index, Barthel Index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 3 months after stroke onset (approximately 2 months and 3 weeks after drug discontinuation)<BR/>Excluded patients with ongoing myocardial infarction<BR/>Exclusions during trial: 4 patients (2 amphetamine and 2 placebo). 3 amphetamine-treated patients died during the treatment period<BR/>Loss to follow up: none (6 amphetamine and 2 placebo patients died, excluding the number of patients who died during the treatment period)<BR/>Patients followed according to the principles of intention to treat<BR/>Imbalances at baseline: the number of patients not alert and the number of smokers were significantly higher in the amphetamine-treated group<BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Platz-2005">
<CHAR_METHODS>
<P>Patient, provider and outcome assessor blinded<BR/>Randomisation procedure: centralised/ pharmacy controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Germany<BR/>26 patients<BR/>Age: range 20 to 80 years, mean 58 years<BR/>46% female<BR/>100% CT or MRI before entry<BR/>All cerebral infarction<BR/>3 weeks to 6 months since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + physiotherapy vs placebo + physiotherapy<BR/>Amount and type of rehabilitation: arm rehabilitation less than 45 minutes/session, 15 sessions during three weeks at a rehabilitation ward<BR/>Type of amphetamine: dexamphetamine<BR/>Dose of amphetamine: 10 mg twice/week<BR/>Duration: 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function with emphasis on the upper extremity, blood pressure, heart rate, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 12 months after treatment discontinuation (13 to 19 months after stroke onset)<BR/>Multicenter study<BR/>Excluded patients with blood pressure equal to or greater than 170 mmHg/110 mmHg, tachycardia (equal to or greater than 100 bpm), myocardial infarct or angina pectoris within the last 4 weeks, decompensated cardiac insufficiency, current medication with any MAO inhibitor, alpha-adrenergic agonist or antagonist, intracerebral haemorrhage within the last 3 months, untreated hyperthyroidism, phaeochrmozytoma, glaucoma, bladder failure (retention), psychosis, epilepsy or history of epileptic seizure and epileptic discharges in EEG<BR/>Exclusions during trial: 2 dexamphetamine and 3 placebo allocated patients did not completely receive the allocated intervention because they refused further medication <BR/>Loss to follow up: 5 dexamphetamine and 1 placebo patients<BR/>No baseline imbalances reported<BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reding-1995">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded<BR/>Randomisation procedure: centralised/pharmacy controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>21 patients<BR/>Age: range unknown, mean 67 years<BR/>Percentage of females included is unknown<BR/>100% CT or MRI before entry<BR/>All cerebral infarction<BR/>7 to 45 days (median 21 days) after stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine vs placebo<BR/>Amount and type of rehabilitation: standard at a rehabilitation unit<BR/>Type of amphetamine: dexamphetamine<BR/>Dose of amphetamine: 5 to 10 mg<BR/>Duration: 17 days (14 days with 10 mg and 3 days with 5 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function, ADL, depression <BR/>Assessment scales: Fugl-Meyer Motor Scale, Barthel ADL Index, Zung depression scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 10 days after drug discontinuation (approximately 5 weeks to 2.5 months after stroke onset) <BR/>Exclusions during trial: none<BR/>Loss to follow up: none<BR/>Imbalances at baseline: the age was significantly higher (9 years) in the amphetamine-treated group<BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sonde-2001">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded<BR/>Randomisation procedure: centralised/pharmacy controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sweden<BR/>40 patients<BR/>Age: range 66 to 91 years, mean 78 years<BR/>40% female<BR/>100% CT before entry<BR/>Cerebral infarction and haemorrhage<BR/>5 to 10 days since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + physiotherapy vs placebo + physiotherapy<BR/>Physiotherapy: more than 30 minutes 5 days/week in addition to the geriatric rehabilitation ward's regular training program<BR/>Type of amphetamine: d,l-amphetamine<BR/>Dose of amphetamine: 10 mg twice/week<BR/>Duration: 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function, ADL<BR/>Assessment scales: Fugl-Meyer motor scale, Barthel Index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 3 months after stroke onset (approximately 1.5 months after drug discontinuation)<BR/>Exclusions during trial: 1 placebo patient (because of acute renal insufficiency and uncontrolled hypertension)<BR/>Patients not followed up according to intention-to-treat principles<BR/>Loss to follow up: none (3 amphetamine patients died after end of treatment)<BR/>Exclusion of patients with serious cardiovascular disease and patients receiving alpha-adrenergic antagonists or agonists, neuroleptics, benzodiazepines or antidepressants<BR/>Imbalances at baseline: the age was significantly higher (5 years) in the amphetamine-treated group<BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Treig-2003">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Germany<BR/>24 patients<BR/>Age: range 34 to 70 years, mean 57 years<BR/>8% female?<BR/>100% CT and/or MR before entry<BR/>All cerebral infarction<BR/>Less than 6 weeks since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + physiotherapy vs placebo + physiotherapy<BR/>Amount and type of rehabilitation: 45 minutes of physiotherapy (neurodevelopmental concept - the Bobath concept) 5 times/week during the study period<BR/>Type of amphetamine: dexamphetamine<BR/>Dose of amphetamine:10 mg every fourth day <BR/>Duration: 36 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function, ADL (primary outcome)<BR/>Assessment scales: Barthel Index, Rivermead motor assessment score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 12 months after the first treatment (approximately 12 months and 3 weeks after stroke onset)<BR/>Exclusion criteria: unstable cardiac dysrhythmia, hypertension not controlled by medication (greater than 160/100 mmHg), untreated hyperthyroidism, history of psychiatric illness or excessive alcohol or drug abuse, medication with alfa-adrenergic antagonists or agonists, major tranquillizers, terminal medical condition such as cancer or AIDS, other coincident neurological disease<BR/>Exclusions during trial: none<BR/>Loss to follow up: 1 amphetamine patient and 1 placebo patient<BR/>No baseline imbalances reported<BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vachalathiti-2001">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded<BR/>Randomisation procedure: pre-numbered or coded identical containers, which were administered serially to participants</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Thailand<BR/>27 patients<BR/>Mean age 62 years<BR/>41% female<BR/>100 % (?) CT scan before entry<BR/>All cerebral infarction<BR/>Entry within 10 days of stroke onset?<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + physiotherapy vs placebo + physiotherapy<BR/>Physiotherapy: Type and amount unknown<BR/>Type of amphetamine: Methamphetamine<BR/>Dose of amphetamine: 10 mg/day<BR/>Duration: 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function<BR/>Assessment scale: Fugl-Meyer motor scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 1 day after drug discontinuation (approximately 2 to 3 weeks post stroke?)<BR/>Exclusions during trial: none<BR/>Loss to follow up: none<BR/>The authors have provided some additional information. The following questions are however still unanswered: Did all patients have a CT scan? How much and what kind of physiotherapy did the patients receive?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Walker_x002d_Batson-1995">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded<BR/>Treatment allocation was known by several members of the research group. Treatment and outcome assessment was performed by blinded personnel.<BR/>Randomisation procedure: unclear whether the randomization was centralised/pharmacy controlled or was done in another way</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>10 patients<BR/>Age: range: 48 to 73 years, mean 65 years<BR/>60% female<BR/>100% CT before entry<BR/>All cerebral infarction<BR/>16 to 30 days since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + physiotherapy vs placebo + physiotherapy<BR/>Physiotherapy: amount unknown. 'Rehabilitative tasks were attempted in each area addressed by the Fugl-Meyer scale'<BR/>Type of amphetamine: dexamphetamine<BR/>Dose of amphetamine: 10 mg every 3 to 4 days<BR/>Duration: 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Motor function<BR/>Assessment scale: Fugl-Meyer motor score<BR/>Adverse events not collected systematically</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 12 months after stroke onset (approximately 10.5 months after drug discontinuation)<BR/>Exclusion criteria: Unstable cardiac dysrhythmia or hypertension, patients receiving alpha-adrenergic antagonists or agonists, major or minor tranquilizers<BR/>Exclusions during trial: none<BR/>Loss to follow up: none<BR/>No baseline imbalances reported<BR/>The authors provided additional information. The following questions are still unanswered: What kind of randomisation procedure was used? How much physiotherapy did the patients receive?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Walker_x002d_Batson-2001">
<CHAR_METHODS>
<P>Patient, provider, and outcome assessor blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>21 patients<BR/>Age: range unknown, mean 57 years<BR/>38% female<BR/>100% CT scan before entry<BR/>All cerebral infarction<BR/>16 to 30 days since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphetamine + speech therapy vs placebo + speech therapy<BR/>Speech therapy: 60 minutes of individual therapy determined from the patient's performance<BR/>Type of amphetamine: dexamphetamine<BR/>Dose of amphetamine: 10 mg every 3 to 4 days<BR/>Duration: 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Language function<BR/>Assessment scale: Porch Index of Communicative Abilities<BR/>Adverse events not collected systematically<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Last follow up: 6 months after stroke onset (approximately 4.5 months after drug discontinuation)<BR/>Exclusions during trial: 3 patients (2 placebo and 1 amphetamine patients were not included in the analysis since they did not complete the study)<BR/>Patients not followed according to the principles of intention to treat<BR/>Loss to follow up: 1 amphetamine patient <BR/>Exclusion criteria: Unstable cardiac dysrhythmia, hypertension, patients receiving alpha-adrenergic antagonists or agonists <BR/>No baseline imbalances reported <BR/>The authors provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living<BR/>bpm: beats per minute<BR/>CT: computed tomography<BR/>EEG: electroencephalogram<BR/>MAO inhibitor: monoamine oxidase inhibitor<BR/>MRI: magnetic resonance imaging<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Benson-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncertain study design (including randomisation procedure). Uncertain intervention and outcome measures. It has not been possible to get more information about the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mazagri-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>In the published abstract no data were reported. Patient records are not longer available according to one of the authors (AS).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McNeil-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single subject experimental design with no subject randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niklasson-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single-case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Unwin-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not possible to elucidate whether patients included in the analysis had been included in randomized placebo-controlled studies. Information has not been provided by the study authors despite repeated requests.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Volpe-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The design of the study makes it necessary to get further information before data can be included. Information has not been provided by the study authors despite repeated requests.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walker_x002d_Batson-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walker_x002d_Batson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Widdig-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case study with only one patient included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wongjitrat-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ziegler-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Too few patients (n = 4) with incomplete data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Bath">
<CHAR_STUDY_NAME>
<P>Stroke trial of amphetamine and recovery</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: (1) ischaemic stroke, (2) clinical stroke 3 to 30 days post ictus, (3) ischaemic stroke on CT/MRI, (4) motor weakness (Motricity Index arm 0 to 99, (5) <BR/>patients expected to stay in hospital for a further 8 days<BR/>Exclusion criteria: (1) premorbid Barthel Index &lt;12/20, (2) dementia, (3) no enteral access in presence of dysphagia, (4) moderate to severe hypertension (systolic blood pressure &gt; 160 mm Hg or diastolic blood pressure &gt; 100 mm Hg)<BR/>Study setting: acute stroke unit or stroke rehabilitation ward<BR/>Number of participants: 42<BR/>Age: no limitations<BR/>Sex: both<BR/>Disease stage: 3 to 30 days post ictus<BR/>Treatment start 3 to 30 days post ictus<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dexamphetamine + physiotherapy vs placebo + physiotherapy<BR/>Physiotherapy: standard level of rehabilitation<BR/>Dose: 5 mg increased to 10 mg if tolerated<BR/>Duration of therapy: 5 weeks (treatment every 3rd or 4th day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: Fugl-Meyer motor scale<BR/>Secondary outcome: blood pressure, transcranial doppler (MCA velocity, pulsatility index, pulsewave analysis, cardiac output), modified Rankin, Barthel Index, Scandinavian Neurological Stroke Scale, Motricity Index - arm, Rivermead - arm, gross function, grip strength, thumb-finding test, Sheffield aphasia screening, star cancellation, modified Mini Mental State Exam, Zung depression score, Extended ADL, EuroQOL, 10-Hole Peg Test, Safety Measures</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Philip Bath<BR/>Stroke Association Professor of Stroke Medicine<BR/>Division of Stroke Medicine<BR/>Institute of Neuroscience<BR/>University of Nottingham<BR/>South Block, D Floor<BR/>Queen's Medical Centre<BR/>Nottingham NG7 2UH, UK</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Cohen">
<CHAR_STUDY_NAME>
<P>Improvement of use dependent plasticity in chronic stroke patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>(1) thromboembolic non-haemorrhagic hemispheric lesions at least 12 months after the stroke, (2) initial severe motor pareses (below MRC grade 2) which subsequently recovered to the point that they have a residual motor deficit but can perform the required tasks, (3) able to contribute and perform simple attentional tasks and other tasks<BR/>Exclusion criteria: (1) more than one stroke in the MCA territory, (2) bilateral motor impairment, (3) cerebellar or brainstem lesion, (4) patients receiving alpha-adrenergic antagonists or agonists, major/minor tranquilizers, clonidine, prazosin, phonation, benzodiaxepines, scopolamine, haloperidol, other neuroleptics, barbiturates and MAO inhibitors, (5) patients or normal volunteers unable to perform the task (wrist or elbow flexion at least MRC grade 2), (6) patients or normal volunteers with history of severe alcohol or drug abuse, psychiatric illness like severe depression, poor motivational capacity, or severe language disturbances, particularly of receptive nature or with serious cognitive deficits (defined as equivalent to a mini-mental state exam score of 23 or less), (7) patients or normal volunteers with severe uncontrolled medical problems (e.g. hypertension, cardiovascular disease, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer or renal disease, any kind of end-stage pulmonary or cardiovascular disease, or a deteriorated condition due to age, uncontrolled epilepsy or others), (8) patients or normal volunteers with unstable cardiac arrhythmia, (9) patients or normal volunteers with history of hyperthyroidism or individuals receiving drugs acting primarily on the central nervous system, (10) patients and normal volunteers with more than moderate to severe microangiopathy, polyneuropathy, diabetes mellitus, or ischaemic peripheral disease, (11) pregnancy, (12) patients and normal volunteers less than 18 years of age, (13) lactating women<BR/>Number or participants: 34</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Motor training alone for about 3 hours<BR/>Motor training, dexamphetamine 10 mg (or placebo), and electrical stimulation for about 6 hours Motor training, dexamphetamine, and no electrical stimulation for about 6 hours Cross-over design</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MRI, TMS</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Mrs Shashi Ravindran at NINDS, NIH, USA<BR/>ravindrs@ninds.nih.gov</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Goldstein">
<CHAR_STUDY_NAME>
<P>The Amphetamine-<BR/>Enhanced Stroke Recovery (AESR) trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: patients with motor deficits resulting from hemispheric ischaemic stroke<BR/>Number of participants: 130</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dexamphetamine + physiotherapy vs placebo + physiotherapy<BR/>Physiotherapy: 60 minutes after each dose<BR/>Dose: 10 mg (given every 4th day)<BR/>Duration: 24 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: Fugl-Meyer motor score<BR/>Several secondary outcomes</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>April 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Dr Larry Goldstein, Medical Center Durham, North Carolina, USA<BR/>golds004@mc.duke.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living<BR/>CT: computed tomography<BR/>MAO inhibitor: monoamine oxidase inhibitor<BR/>MCA: middle cerebral artery<BR/>MRC: Medical Research Council<BR/>MRI: magnetic resonance imaging<BR/>TMS: transcranial magnetic stimulation <BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Crisostomo-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gladstone-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Martinsson-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Platz-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Reding-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sonde-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Treig-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vachalathiti-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Walker_x002d_Batson-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Walker_x002d_Batson-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Adverse events during the intervention period</TITLE>
<TABLE COLS="3" ROWS="24">
<TR>
<TH>
<P>Adverse events</P>
</TH>
<TH>
<P>D-amphetamine (n=79)</P>
</TH>
<TH>
<P>Placebo (n=64)</P>
</TH>
</TR>
<TR>
<TD>
<P>Progression of stroke</P>
</TD>
<TD>
<P>13 (17%; 95% CI 9 to 27)</P>
</TD>
<TD>
<P>6 (9%; 95% CI 4 to 19)</P>
</TD>
</TR>
<TR>
<TD>
<P>Fever</P>
</TD>
<TD>
<P>10 (13%; 95% CI 6 to 22)</P>
</TD>
<TD>
<P>6 (9%; 95% CI 4 to 19)</P>
</TD>
</TR>
<TR>
<TD>
<P>Confusion, hallucination, psychosis, agitation</P>
</TD>
<TD>
<P>4 (5%; 95% CI 1 to 13 )</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>4 (5%; 95% CI 1 to 13)</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Insomnia</P>
</TD>
<TD>
<P>4 (5%; 95% CI 1 to 13)</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Dryness of mouth</P>
</TD>
<TD>
<P>3 (4%; 95% CI 1 to 11)</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Seizures</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 9)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Shoulder discomfort</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 9)</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Tension in forearm and fingers</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 9)</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Acute renal failure</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Delirium</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Falls</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Heart sensation</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lack of appetite</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Leg deep venous thrombosis</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>2 (3%; 95% CI 0 to 11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pneumonia</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Sensation of warmth</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Urinary tract infection</P>
</TD>
<TD>
<P>1 (1%; 95% CI 0 to 7)</P>
</TD>
<TD>
<P>4 (6%; 95% CI 2 to 15)</P>
</TD>
</TR>
<TR>
<TD>
<P>Abdominal pain</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 4)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Angina</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 4)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradychardia</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 4)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Gout</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 4)</P>
</TD>
<TD>
<P>1 (2%; 95% CI 0 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Presyncope/syncope</P>
</TD>
<TD>
<P>0 (0%; 95% CI 0 to 4)</P>
</TD>
<TD>
<P>4 (6%; 95% CI 0 to 11)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Study details of included studies</TITLE>
<TABLE COLS="6" ROWS="11">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Onset to stroke</P>
</TH>
<TH>
<P>Treatment length</P>
</TH>
<TH>
<P>Treatment to rehab</P>
</TH>
<TH>
<P>Rehab session</P>
</TH>
</TR>
<TR>
<TD>
<P>Crisostomo 1988</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>3 to 10 days</P>
</TD>
<TD>
<P>1 day</P>
</TD>
<TD>
<P>Less than 180 minutes</P>
</TD>
<TD>
<P>More than 45 minutes</P>
</TD>
</TR>
<TR>
<TD>
<P>Gladstone 2006</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>5 to 10 days</P>
</TD>
<TD>
<P>5 weeks, twice per week</P>
</TD>
<TD>
<P>90 minutes</P>
</TD>
<TD>
<P>60 minutes</P>
</TD>
</TR>
<TR>
<TD>
<P>Martinsson 2003</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>Less than 72 hours</P>
</TD>
<TD>
<P>5 days, every day</P>
</TD>
<TD>
<P>Not prespecified</P>
</TD>
<TD>
<P>Standard rehabilitation at a stroke unit</P>
</TD>
</TR>
<TR>
<TD>
<P>Platz 2005</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>3 weeks to 6 months</P>
</TD>
<TD>
<P>36 days, twice a week</P>
</TD>
<TD>
<P>120 minutes</P>
</TD>
<TD>
<P>Approximately 45 minutes</P>
</TD>
</TR>
<TR>
<TD>
<P>Reding 1995</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>17 days, every day</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Standard rehabilitation during inpatient rehabilitation</P>
</TD>
</TR>
<TR>
<TD>
<P>Sonde 2001</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>5 to 10 days</P>
</TD>
<TD>
<P>5 weeks, twice a week</P>
</TD>
<TD>
<P>60 minutes</P>
</TD>
<TD>
<P>At least 30 minutes</P>
</TD>
</TR>
<TR>
<TD>
<P>Treig 2003</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>Less than 6 weeks</P>
</TD>
<TD>
<P>36 days, every 4th day</P>
</TD>
<TD>
<P>Less than 60 minutes</P>
</TD>
<TD>
<P>45 minutes</P>
</TD>
</TR>
<TR>
<TD>
<P>Vachalatiti 2001</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>Approximately 5 to 6 days</P>
</TD>
<TD>
<P>5 days</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
</TR>
<TR>
<TD>
<P>Walker-Batson 1995</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>16 to 30 days</P>
</TD>
<TD>
<P>5 weeks, every 4th day</P>
</TD>
<TD>
<P>'During the peak period of drug action'</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
</TR>
<TR>
<TD>
<P>Walker-Batson 2001</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>16 to 45 days</P>
</TD>
<TD>
<P>5 weeks, every 3rd to 4th day</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>60 minutes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Amphetamine versus placebo for stroke</NAME>
<DICH_OUTCOME CHI2="0.5913008384296523" CI_END="3.2692948885975968" CI_START="0.6394841558642619" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4459122663931516" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.5144540954701473" LOG_CI_START="-0.19417021131975176" LOG_EFFECT_SIZE="0.16014194207519775" METHOD="PETO" NO="1" P_CHI2="0.7440475175288983" P_Q="1.0" P_Z="0.3756907395731045" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="45" WEIGHT="99.99999999999999" Z="0.8858641620791808">
<NAME>Dead or dependent at final follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9528914152495855" CI_START="0.3304695234995805" EFFECT_SIZE="1.1429392557975742" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.5969148845666936" LOG_CI_START="-0.4808685857585371" LOG_EFFECT_SIZE="0.05802314940407827" ORDER="24168" O_E="0.3333333333333339" SE="0.6330953455832623" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" VAR="2.494949494949495" WEIGHT="43.22838920802962"/>
<DICH_DATA CI_END="7.403114252058683" CI_START="0.5955886085404324" EFFECT_SIZE="2.0998120192649328" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8694144518887189" LOG_CI_START="-0.22505361732574164" LOG_EFFECT_SIZE="0.3221804172814886" ORDER="24169" O_E="1.7948717948717956" SE="0.6428959615608923" STUDY_ID="STD-Sonde-2001" TOTAL_1="20" TOTAL_2="19" VAR="2.4194608809993423" WEIGHT="41.920446425533356"/>
<DICH_DATA CI_END="8.306206947635363" CI_START="0.12039189563952328" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9194027472766823" LOG_CI_START="-0.9194027472766824" LOG_EFFECT_SIZE="0.0" ORDER="24170" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-Treig-2003" TOTAL_1="11" TOTAL_2="11" VAR="0.8571428571428571" WEIGHT="14.851164366437013"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1690379036234022" CI_END="8.603824590023828" CI_START="0.9247269001972573" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.8206715588621223" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.9346915476520509" LOG_CI_START="-0.03398650861182753" LOG_EFFECT_SIZE="0.45035251952011174" METHOD="PETO" NO="2" P_CHI2="0.5573741224077069" P_Q="1.0" P_Z="0.06838953328566919" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="134" WEIGHT="100.00000000000001" Z="1.8224315352217302">
<NAME>Death from all causes at final follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24171" O_E="0.0" SE="0.0" STUDY_ID="STD-Crisostomo-1988" TOTAL_1="4" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="19.16827667869478" CI_START="0.07076014906601114" EFFECT_SIZE="1.164624452397848" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.282583069446863" LOG_CI_START="-1.1502112608601398" LOG_EFFECT_SIZE="0.0661859042933616" ORDER="24180" O_E="0.07462686567164178" SE="1.4290354321484877" STUDY_ID="STD-Gladstone-2006" TOTAL_1="31" TOTAL_2="36" VAR="0.489681848559104" WEIGHT="15.854338751463228"/>
<DICH_DATA CI_END="10.058682695274456" CI_START="0.5805784592400809" EFFECT_SIZE="2.416579090617004" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.0025411083905647" LOG_CI_START="-0.23613908150247295" LOG_EFFECT_SIZE="0.3832010134440458" ORDER="24172" O_E="1.666666666666667" SE="0.7276068751089989" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" VAR="1.8888888888888888" WEIGHT="61.15620661954116"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24178" O_E="0.0" SE="0.0" STUDY_ID="STD-Platz-2005" TOTAL_1="15" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24173" O_E="0.0" SE="0.0" STUDY_ID="STD-Reding-1995" TOTAL_1="12" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="80.18093113183994" CI_START="0.7651992255545326" EFFECT_SIZE="7.832904085096745" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.904071095355161" LOG_CI_START="-0.1162254781867742" LOG_EFFECT_SIZE="0.8939228085841935" ORDER="24174" O_E="1.4615384615384615" SE="1.18673220792786" STUDY_ID="STD-Sonde-2001" TOTAL_1="20" TOTAL_2="19" VAR="0.710059171597633" WEIGHT="22.98945462899563"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24179" O_E="0.0" SE="0.0" STUDY_ID="STD-Treig-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24175" O_E="0.0" SE="0.0" STUDY_ID="STD-Vachalathiti-2001" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24176" O_E="0.0" SE="0.0" STUDY_ID="STD-Walker_x002d_Batson-1995" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24177" O_E="0.0" SE="0.0" STUDY_ID="STD-Walker_x002d_Batson-2001" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06220011783584867" CI_END="45.63091800911913" CI_START="0.7072872739212681" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.6810357862976675" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.6592592060569986" LOG_CI_START="-0.15040415602117388" LOG_EFFECT_SIZE="0.7544275250179123" METHOD="PETO" NO="3" P_CHI2="0.8030517637274079" P_Q="1.0" P_Z="0.10222269827471818" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="137" WEIGHT="100.0" Z="1.6341721990577884">
<NAME>Death from all causes after end of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24181" O_E="0.0" SE="0.0" STUDY_ID="STD-Crisostomo-1988" TOTAL_1="4" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="442.38452381838596" CI_START="0.17040133636371638" EFFECT_SIZE="8.68233344471861" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.645799925399172" LOG_CI_START="-0.7685270036238254" LOG_EFFECT_SIZE="0.9386364608876735" ORDER="24190" O_E="0.5373134328358209" SE="2.0055925392989864" STUDY_ID="STD-Gladstone-2006" TOTAL_1="31" TOTAL_2="36" VAR="0.24860770773000665" WEIGHT="28.092176022334606"/>
<DICH_DATA CI_END="56.16947456500513" CI_START="0.4125011401245668" EFFECT_SIZE="4.813519741131481" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.749500361305621" LOG_CI_START="-0.38457484675254394" LOG_EFFECT_SIZE="0.6824627572765386" ORDER="24182" O_E="1.0" SE="1.2535663410560174" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" VAR="0.6363636363636364" WEIGHT="71.9078239776654"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24189" O_E="0.0" SE="0.0" STUDY_ID="STD-Platz-2005" TOTAL_1="15" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24183" O_E="0.0" SE="0.0" STUDY_ID="STD-Reding-1995" TOTAL_1="9" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24184" O_E="0.0" SE="0.0" STUDY_ID="STD-Sonde-2001" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24188" O_E="0.0" SE="0.0" STUDY_ID="STD-Treig-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24185" O_E="0.0" SE="0.0" STUDY_ID="STD-Vachalathiti-2001" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24186" O_E="0.0" SE="0.0" STUDY_ID="STD-Walker_x002d_Batson-1995" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24187" O_E="0.0" SE="0.0" STUDY_ID="STD-Walker_x002d_Batson-2001" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.20573528649644268" CI_END="15.234326465320525" CI_START="1.5577185016309363" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.39602248347573" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.6501307899248194" P_Q="1.0" P_Z="0.016109279121033722" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="2.406430267605858">
<NAME>Systolic blood pressure during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.527071913763073" CI_START="-0.14707191376307804" EFFECT_SIZE="10.189999999999998" ESTIMABLE="YES" MEAN_1="149.53" MEAN_2="139.34" ORDER="24191" SD_1="17.41" SD_2="16.3" SE="5.274113195599806" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="43.76246029704493"/>
<CONT_DATA CI_END="16.118748674550048" CI_START="-2.1187486745500497" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="137.0" MEAN_2="130.0" ORDER="24192" SD_1="11.0" SD_2="13.0" SE="4.652508284069286" STUDY_ID="STD-Platz-2005" TOTAL_1="16" TOTAL_2="12" WEIGHT="56.237539702955075"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="22.04753230002118" CI_START="5.212467699978822" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="13.630000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.001505346193611748" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="3.17365091776526">
<NAME>Change in systolic blood pressure during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.04753230002118" CI_START="5.212467699978822" EFFECT_SIZE="13.630000000000003" ESTIMABLE="YES" MEAN_1="-4.04" MEAN_2="-17.67" ORDER="24193" SD_1="15.09" SD_2="12.76" SE="4.29473825356874" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.22571118833529613" CI_END="8.786777695977955" CI_START="1.0635919389239885" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.925184817450972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.6347223349982218" P_Q="1.0" P_Z="0.012426570963089655" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="2.49979352123977">
<NAME>Diastolic blood pressure during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.230713649094133" CI_START="-1.010713649094134" EFFECT_SIZE="4.109999999999999" ESTIMABLE="YES" MEAN_1="83.11" MEAN_2="79.0" ORDER="24194" SD_1="9.15" SD_2="7.78" SE="2.612657012825577" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="56.86852817719728"/>
<CONT_DATA CI_END="11.879891953620163" CI_START="0.12010804637983696" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="78.0" ORDER="24195" SD_1="6.0" SD_2="9.0" SE="3.0" STUDY_ID="STD-Platz-2005" TOTAL_1="16" TOTAL_2="12" WEIGHT="43.13147182280273"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1491266727247387E-31" CI_END="12.76528268153577" CI_START="2.494717318464229" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.629999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="0.003589923491056363" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="2.912113340091392">
<NAME>Change in diastolic blood pressure during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.765282681535771" CI_START="2.494717318464229" EFFECT_SIZE="7.63" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-8.93" ORDER="24196" SD_1="9.62" SD_2="7.53" SE="2.6200903292316724" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.06484300367689945" CI_END="17.772042932052017" CI_START="3.3362920909031253" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="10.554167511477571" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.7989989297367525" P_Q="1.0" P_Z="0.0041581119230635274" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="2.8659109507950555">
<NAME>Heart rate during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.550016007833733" CI_START="2.689983992166278" EFFECT_SIZE="11.120000000000005" ESTIMABLE="YES" MEAN_1="85.65" MEAN_2="74.53" ORDER="24197" SD_1="17.4" SD_2="11.23" SE="4.3011076092870155" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="73.30978827724367"/>
<CONT_DATA CI_END="22.971189152198903" CI_START="-4.971189152198901" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="73.0" MEAN_2="64.0" ORDER="24198" SD_1="15.0" SD_2="21.0" SE="7.128288714691626" STUDY_ID="STD-Platz-2005" TOTAL_1="16" TOTAL_2="12" WEIGHT="26.690211722756338"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.39827189973241" CI_START="3.5617281002675876" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.979999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.0011607390353723067" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="3.248356100777982">
<NAME>Change in heart rate during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.39827189973241" CI_START="3.5617281002675876" EFFECT_SIZE="8.979999999999999" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="-0.28" ORDER="24199" SD_1="10.97" SD_2="7.38" SE="2.7644752365201852" STUDY_ID="STD-Martinsson-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.892766332509212" CI_END="0.19051089667544463" CI_START="-0.3420944243921269" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.07579176385834113" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.5523251635218804" P_Q="1.0" P_Z="0.5769668518241995" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="114" TOTAL_2="112" UNITS="" WEIGHT="100.00000000000001" Z="0.55782066611485">
<NAME>Motor function at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0328485711514799" CI_START="-1.7870886517074274" EFFECT_SIZE="-0.3771200402779737" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="42.5" ORDER="24200" SD_1="32.8" SD_2="24.2" SE="0.7193849593926757" STUDY_ID="STD-Crisostomo-1988" TOTAL_1="4" TOTAL_2="4" WEIGHT="3.5672382948862453"/>
<CONT_DATA CI_END="0.5718138979049614" CI_START="-0.3954804218131471" EFFECT_SIZE="0.08816673804590715" ESTIMABLE="YES" MEAN_1="58.77" MEAN_2="56.16" ORDER="24206" SD_1="30.83" SD_2="27.36" SE="0.24676328936347874" STUDY_ID="STD-Gladstone-2006" TOTAL_1="35" TOTAL_2="31" WEIGHT="30.317523794612917"/>
<CONT_DATA CI_END="0.5319537855882963" CI_START="-0.8537996108184596" EFFECT_SIZE="-0.16092291261508157" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="69.4" ORDER="24201" SD_1="43.0" SD_2="46.0" SE="0.3535150154128856" STUDY_ID="STD-Martinsson-2003" TOTAL_1="13" TOTAL_2="21" WEIGHT="14.77199318475763"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="24208" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Platz-2005" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.9712428151652187" CI_START="-0.7587527979260152" EFFECT_SIZE="0.10624500861960175" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="42.0" ORDER="24202" SD_1="31.2" SD_2="42.0" SE="0.4413335211098823" STUDY_ID="STD-Reding-1995" TOTAL_1="12" TOTAL_2="9" WEIGHT="9.478093711099183"/>
<CONT_DATA CI_END="0.7582834104312816" CI_START="-0.5513600673483229" EFFECT_SIZE="0.10346167154147934" ESTIMABLE="YES" MEAN_1="65.2" MEAN_2="62.5" ORDER="24203" SD_1="23.3" SD_2="27.8" SE="0.33409886306837905" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="17" WEIGHT="16.53883190300126"/>
<CONT_DATA CI_END="0.27001878785744704" CI_START="-1.4447884428790005" EFFECT_SIZE="-0.5873848275107767" ESTIMABLE="YES" MEAN_1="7.09" MEAN_2="10.36" ORDER="24207" SD_1="4.53" SD_2="6.07" SE="0.43745886257671773" STUDY_ID="STD-Treig-2003" TOTAL_1="11" TOTAL_2="11" WEIGHT="9.646735918710592"/>
<CONT_DATA CI_END="0.8403982748714667" CI_START="-0.6702172554098145" EFFECT_SIZE="0.08509050973082613" ESTIMABLE="YES" MEAN_1="46.3" MEAN_2="44.2" ORDER="24204" SD_1="23.2" SD_2="24.7" SE="0.38536818589444083" STUDY_ID="STD-Vachalathiti-2001" TOTAL_1="14" TOTAL_2="13" WEIGHT="12.430915418825627"/>
<CONT_DATA CI_END="0.04942614112025945" CI_START="-2.90554232595005" EFFECT_SIZE="-1.4280580924148953" ESTIMABLE="YES" MEAN_1="29.6" MEAN_2="50.2" ORDER="24205" SD_1="8.4" SD_2="16.4" SE="0.7538323383436439" STUDY_ID="STD-Walker_x002d_Batson-1995" TOTAL_1="5" TOTAL_2="5" WEIGHT="3.248667774106555"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.621530683911923" CI_END="-1.8960511341273785" CI_START="-10.382204707055934" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.139127920591656" ESTIMABLE="YES" I2="48.03321670677145" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.08669745860406186" P_Q="1.0" P_Z="0.004571266466542434" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="89" UNITS="" WEIGHT="100.0" Z="2.8357887981731493">
<NAME>Relative change in motor function until final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.5568853507172395" CI_START="-15.703114649282762" EFFECT_SIZE="-8.63" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="9.63" ORDER="24209" SD_1="0.91" SD_2="7.16" SE="3.6087982764349684" STUDY_ID="STD-Crisostomo-1988" TOTAL_1="4" TOTAL_2="4" WEIGHT="35.986564404932956"/>
<CONT_DATA CI_END="8.426676550443377" CI_START="-7.6266765504433796" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="29.66" MEAN_2="29.26" ORDER="24213" SD_1="17.55" SD_2="15.72" SE="4.095318390417772" STUDY_ID="STD-Gladstone-2006" TOTAL_1="35" TOTAL_2="31" WEIGHT="27.94410838769071"/>
<CONT_DATA CI_END="4.70179696561571" CI_START="-28.841796965615703" EFFECT_SIZE="-12.069999999999997" ESTIMABLE="YES" MEAN_1="20.69" MEAN_2="32.76" ORDER="24210" SD_1="19.47" SD_2="30.42" SE="8.55719650866521" STUDY_ID="STD-Martinsson-2003" TOTAL_1="13" TOTAL_2="21" WEIGHT="6.400333287383756"/>
<CONT_DATA CI_END="13.267484410869063" CI_START="-9.987484410869062" EFFECT_SIZE="1.6400000000000006" ESTIMABLE="YES" MEAN_1="24.53" MEAN_2="22.89" ORDER="24211" SD_1="20.88" SD_2="14.43" SE="5.932499016607027" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="17" WEIGHT="13.31650481917115"/>
<CONT_DATA CI_END="1.4515137763306765" CI_START="-24.73151377633068" EFFECT_SIZE="-11.64" ESTIMABLE="YES" MEAN_1="14.91" MEAN_2="26.55" ORDER="24214" SD_1="14.76" SD_2="16.52" SE="6.679466500198405" STUDY_ID="STD-Treig-2003" TOTAL_1="11" TOTAL_2="11" WEIGHT="10.504661159424524"/>
<CONT_DATA CI_END="-5.853778876187896" CI_START="-40.9462211238121" EFFECT_SIZE="-23.4" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="34.4" ORDER="24212" SD_1="5.24" SD_2="19.32" SE="8.952318135544559" STUDY_ID="STD-Walker_x002d_Batson-1995" TOTAL_1="5" TOTAL_2="5" WEIGHT="5.847827941396911"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.244429061767619" CI_START="-13.64442906176761" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.6999999999999957" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6287231643165554" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.4835247894971922">
<NAME>Time to complete motor task</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.244429061767619" CI_START="-13.64442906176761" EFFECT_SIZE="-2.6999999999999957" ESTIMABLE="YES" MEAN_1="45.1" MEAN_2="47.8" ORDER="24215" SD_1="13.4" SD_2="11.5" SE="5.583994985671101" STUDY_ID="STD-Platz-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.6087544089032364" CI_START="-2.8887544089032375" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6400000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.5769743627536279" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="8" UNITS="" WEIGHT="100.00000000000001" Z="0.5578096679385371">
<NAME>Time to walk 10 metres</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6087544089032364" CI_START="-2.8887544089032375" EFFECT_SIZE="-0.6400000000000006" ESTIMABLE="YES" MEAN_1="8.26" MEAN_2="8.9" ORDER="24216" SD_1="1.74" SD_2="2.8" SE="1.1473447607410772" STUDY_ID="STD-Platz-2005" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3030240404167912" CI_END="13.489125670866995" CI_START="-5.749229067219682" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.8699483018236567" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" NO="14" P_CHI2="0.7284152363073659" P_Q="1.0" P_Z="0.43038984263487845" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="58" UNITS="" WEIGHT="100.00000000000001" Z="0.7885247358070768">
<NAME>Activities of daily living at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.975543431494039" CI_START="-32.41554343149404" EFFECT_SIZE="-8.219999999999999" ESTIMABLE="YES" MEAN_1="72.69" MEAN_2="80.91" ORDER="24217" SD_1="38.38" SD_2="28.65" SE="12.344891856353176" STUDY_ID="STD-Martinsson-2003" TOTAL_1="13" TOTAL_2="21" WEIGHT="15.805385903621346"/>
<CONT_DATA CI_END="34.377358124044946" CI_START="-18.37735812404495" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="63.0" ORDER="24218" SD_1="31.2" SD_2="30.0" SE="13.458083073008577" STUDY_ID="STD-Reding-1995" TOTAL_1="12" TOTAL_2="9" WEIGHT="13.298825089508872"/>
<CONT_DATA CI_END="24.22861421082844" CI_START="-8.22861421082844" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="77.1" MEAN_2="69.1" ORDER="24219" SD_1="20.8" SD_2="27.9" SE="8.280057357603342" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="17" WEIGHT="35.13281858200761"/>
<CONT_DATA CI_END="19.70500280742662" CI_START="-12.465002807426611" EFFECT_SIZE="3.6200000000000045" ESTIMABLE="YES" MEAN_1="80.9" MEAN_2="77.28" ORDER="24220" SD_1="20.47" SD_2="17.94" SE="8.206784887019897" STUDY_ID="STD-Treig-2003" TOTAL_1="11" TOTAL_2="11" WEIGHT="35.76297042486219"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0568072642147617" CI_END="8.756625910757005" CI_START="-9.296207482649066" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2697907859460298" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" NO="15" P_CHI2="0.5895454445205436" P_Q="1.0" P_Z="0.9532855173482311" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="0.05858141071729098">
<NAME>Relative change in activities of daily living until final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.96179637150373" CI_START="-27.501796371503737" EFFECT_SIZE="-8.770000000000003" ESTIMABLE="YES" MEAN_1="34.33" MEAN_2="43.1" ORDER="24221" SD_1="28.2" SD_2="25.17" SE="9.557214581113609" STUDY_ID="STD-Martinsson-2003" TOTAL_1="13" TOTAL_2="21" WEIGHT="23.22051784998854"/>
<CONT_DATA CI_END="17.007603800415943" CI_START="-10.84760380041594" EFFECT_SIZE="3.080000000000002" ESTIMABLE="YES" MEAN_1="26.32" MEAN_2="23.24" ORDER="24222" SD_1="20.87" SD_2="21.65" SE="7.106050881687165" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="17" WEIGHT="42.002771642895766"/>
<CONT_DATA CI_END="16.66633197528622" CI_START="-13.946331975286206" EFFECT_SIZE="1.3600000000000065" ESTIMABLE="YES" MEAN_1="49.09" MEAN_2="47.73" ORDER="24223" SD_1="17.15" SD_2="19.41" SE="7.809496549947145" STUDY_ID="STD-Treig-2003" TOTAL_1="11" TOTAL_2="11" WEIGHT="34.77671050711569"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.984069252061465" CI_START="-14.904069252061467" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.960000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.47820471776244533" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.709193006734368">
<NAME>Neurological function at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.984069252061465" CI_START="-14.904069252061467" EFFECT_SIZE="-3.960000000000001" ESTIMABLE="YES" MEAN_1="43.31" MEAN_2="47.27" ORDER="24224" SD_1="16.49" SD_2="14.68" SE="5.583811405917092" STUDY_ID="STD-Martinsson-2003" TOTAL_1="13" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.31207127396276" CI_START="-11.612071273962757" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.6499999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.3689225686836025" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.8984934067301664">
<NAME>Relative change in neurological function until final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.31207127396276" CI_START="-11.612071273962757" EFFECT_SIZE="-3.6499999999999986" ESTIMABLE="YES" MEAN_1="18.6" MEAN_2="22.25" ORDER="24225" SD_1="9.6" SD_2="14.06" SE="4.062355908969022" STUDY_ID="STD-Martinsson-2003" TOTAL_1="13" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.597079543821248" CI_START="-21.997079543821254" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.6436946269632613" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="11" UNITS="" WEIGHT="99.99999999999999" Z="0.46253930117012637">
<NAME>Language function at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.597079543821248" CI_START="-21.997079543821254" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="57.2" ORDER="24226" SD_1="19.7" SD_2="20.8" SE="9.080309477216083" STUDY_ID="STD-Walker_x002d_Batson-2001" TOTAL_1="9" TOTAL_2="11" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.6005461786331834" CI_START="-14.419453821366812" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.509999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.033145420082909514" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="11" UNITS="" WEIGHT="100.00000000000001" Z="2.1303173744902537">
<NAME>Change in language function until final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6005461786331834" CI_START="-14.419453821366812" EFFECT_SIZE="-7.509999999999998" ESTIMABLE="YES" MEAN_1="17.67" MEAN_2="25.18" ORDER="24227" SD_1="8.06" SD_2="7.57" SE="3.5252963196608227" STUDY_ID="STD-Walker_x002d_Batson-2001" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.318502162254745" CI_START="-10.318502162254745" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.20" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.6374764822643582" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.4712300234610512">
<NAME>Depression at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.318502162254745" CI_START="-10.318502162254745" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="39.0" ORDER="24228" SD_1="10.4" SD_2="9.0" SE="4.244211744639202" STUDY_ID="STD-Reding-1995" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.302358551348787" CI_END="0.26740708888128883" CI_START="-0.34621309254496213" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.03940300183183666" ESTIMABLE="YES" I2="17.834765879966742" I2_Q="0.0" ID="CMP-001.21" NO="21" P_CHI2="0.29378810437294633" P_Q="1.0" P_Z="0.8012619605677993" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="93" UNITS="" WEIGHT="100.0" Z="0.251714225870674">
<NAME>Intention-to-treat analysis of motor function at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0328485711514799" CI_START="-1.7870886517074274" EFFECT_SIZE="-0.3771200402779737" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="42.5" ORDER="24229" SD_1="32.8" SD_2="24.2" SE="0.7193849593926757" STUDY_ID="STD-Crisostomo-1988" TOTAL_1="4" TOTAL_2="4" WEIGHT="4.735004423435431"/>
<CONT_DATA CI_END="0.7278093202952464" CI_START="-0.5126538982573637" EFFECT_SIZE="0.1075777110189413" ESTIMABLE="YES" MEAN_1="53.63" MEAN_2="48.28" ORDER="24230" SD_1="45.57" SD_2="50.37" SE="0.31645051346280484" STUDY_ID="STD-Martinsson-2003" TOTAL_1="15" TOTAL_2="30" WEIGHT="24.469860119485983"/>
<CONT_DATA CI_END="0.9712428151652187" CI_START="-0.7587527979260152" EFFECT_SIZE="0.10624500861960175" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="42.0" ORDER="24231" SD_1="31.2" SD_2="42.0" SE="0.4413335211098823" STUDY_ID="STD-Reding-1995" TOTAL_1="12" TOTAL_2="9" WEIGHT="12.580829184337205"/>
<CONT_DATA CI_END="0.9501696860131736" CI_START="-0.3144105185640496" EFFECT_SIZE="0.317879583724562" ESTIMABLE="YES" MEAN_1="63.1" MEAN_2="53.0" ORDER="24232" SD_1="27.23" SD_2="34.41" SE="0.32260291886791553" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="20" WEIGHT="23.545423760177012"/>
<CONT_DATA CI_END="0.18521697168968565" CI_START="-1.4632247547980082" EFFECT_SIZE="-0.6390038915541613" ESTIMABLE="YES" MEAN_1="7.75" MEAN_2="11.58" ORDER="24235" SD_1="4.88" SD_2="6.57" SE="0.42052857590506554" STUDY_ID="STD-Treig-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="13.856452941322283"/>
<CONT_DATA CI_END="0.8403982748714667" CI_START="-0.6702172554098145" EFFECT_SIZE="0.08509050973082613" ESTIMABLE="YES" MEAN_1="46.3" MEAN_2="44.2" ORDER="24233" SD_1="23.2" SD_2="24.7" SE="0.38536818589444083" STUDY_ID="STD-Vachalathiti-2001" TOTAL_1="14" TOTAL_2="13" WEIGHT="16.500282467776106"/>
<CONT_DATA CI_END="0.04942614112025945" CI_START="-2.90554232595005" EFFECT_SIZE="-1.4280580924148953" ESTIMABLE="YES" MEAN_1="29.6" MEAN_2="50.2" ORDER="24234" SD_1="8.4" SD_2="16.4" SE="0.7538323383436439" STUDY_ID="STD-Walker_x002d_Batson-1995" TOTAL_1="5" TOTAL_2="5" WEIGHT="4.312147103465987"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.52590724541572" CI_END="-2.362647339171886" CI_START="-13.255608235035671" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.809127787103779" ESTIMABLE="YES" I2="58.00924891511017" I2_Q="0.0" ID="CMP-001.22" NO="22" P_CHI2="0.049217661088562625" P_Q="1.0" P_Z="0.0049513268823321134" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="71" UNITS="" WEIGHT="99.99999999999999" Z="2.8101834496084788">
<NAME>Intention-to-treat analysis of relative change in motor function until final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.5568853507172395" CI_START="-15.703114649282762" EFFECT_SIZE="-8.63" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="9.63" ORDER="24236" SD_1="0.91" SD_2="7.16" SE="3.6087982764349684" STUDY_ID="STD-Crisostomo-1988" TOTAL_1="4" TOTAL_2="4" WEIGHT="59.29396633451117"/>
<CONT_DATA CI_END="52.98490641507851" CI_START="-18.524906415078515" EFFECT_SIZE="17.23" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="-14.82" ORDER="24237" SD_1="48.76" SD_2="72.31" SE="18.242634404054694" STUDY_ID="STD-Martinsson-2003" TOTAL_1="15" TOTAL_2="30" WEIGHT="2.320387977014443"/>
<CONT_DATA CI_END="42.739257614008636" CI_START="-5.659257614008638" EFFECT_SIZE="18.54" ESTIMABLE="YES" MEAN_1="22.89" MEAN_2="4.35" ORDER="24238" SD_1="15.49" SD_2="52.88" SE="12.346786882253598" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="20" WEIGHT="5.065564062226708"/>
<CONT_DATA CI_END="3.6913156897286736" CI_START="-18.691315689728675" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="22.5" ORDER="24240" SD_1="14.74" SD_2="13.19" SE="5.709959865591584" STUDY_ID="STD-Treig-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="23.684793600818047"/>
<CONT_DATA CI_END="-5.853778876187896" CI_START="-40.9462211238121" EFFECT_SIZE="-23.4" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="34.4" ORDER="24239" SD_1="5.24" SD_2="19.32" SE="8.952318135544559" STUDY_ID="STD-Walker_x002d_Batson-1995" TOTAL_1="5" TOTAL_2="5" WEIGHT="9.635288025429617"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.172128552443508" CI_END="20.02294968984606" CI_START="-0.29722924156913777" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.862860224138462" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.23" NO="23" P_CHI2="0.7596965537737095" P_Q="1.0" P_Z="0.05708935834319181" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="71" UNITS="" WEIGHT="99.99999999999999" Z="1.902626043708537">
<NAME>Intention-to-treat analysis of activities of daily living at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="32.168120778444234" CI_START="-22.828120778444248" EFFECT_SIZE="4.669999999999995" ESTIMABLE="YES" MEAN_1="62.87" MEAN_2="58.2" ORDER="24241" SD_1="43.99" SD_2="45.11" SE="14.029911261301692" STUDY_ID="STD-Martinsson-2003" TOTAL_1="15" TOTAL_2="30" WEIGHT="13.65177223889453"/>
<CONT_DATA CI_END="34.377358124044946" CI_START="-18.37735812404495" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="63.0" ORDER="24242" SD_1="31.2" SD_2="30.0" SE="13.458083073008577" STUDY_ID="STD-Reding-1995" TOTAL_1="12" TOTAL_2="9" WEIGHT="14.836534569269764"/>
<CONT_DATA CI_END="37.341045359580264" CI_START="-0.32104535958027114" EFFECT_SIZE="18.509999999999998" ESTIMABLE="YES" MEAN_1="77.11" MEAN_2="58.6" ORDER="24243" SD_1="20.84" SD_2="37.27" SE="9.607852750416411" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="20" WEIGHT="29.110268112159673"/>
<CONT_DATA CI_END="21.852971154839224" CI_START="-9.352971154839226" EFFECT_SIZE="6.25" ESTIMABLE="YES" MEAN_1="80.83" MEAN_2="74.58" ORDER="24244" SD_1="19.52" SD_2="19.48" SE="7.960845851206181" STUDY_ID="STD-Treig-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="42.40142507967602"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2113136129565207" CI_END="20.22417698664629" CI_START="-4.017376839072963" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.103400073786664" ESTIMABLE="YES" I2="9.556021892073236" I2_Q="0.0" ID="CMP-001.24" NO="24" P_CHI2="0.3309936887999332" P_Q="1.0" P_Z="0.19007990747886966" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="1.3103427619470962">
<NAME>Intention-to-treat analysis of relative change in activities of daily living until final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="58.88175669837495" CI_START="-19.221756698374953" EFFECT_SIZE="19.83" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="-4.83" ORDER="24245" SD_1="57.1" SD_2="73.41" SE="19.92473178405839" STUDY_ID="STD-Martinsson-2003" TOTAL_1="15" TOTAL_2="30" WEIGHT="9.633403828956677"/>
<CONT_DATA CI_END="46.82810167676536" CI_START="-3.3281016767653604" EFFECT_SIZE="21.75" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="3.25" ORDER="24246" SD_1="21.73" SD_2="52.7" SE="12.795184949610414" STUDY_ID="STD-Sonde-2001" TOTAL_1="19" TOTAL_2="20" WEIGHT="23.359933290518857"/>
<CONT_DATA CI_END="16.46714956867648" CI_START="-13.147149568676486" EFFECT_SIZE="1.6599999999999966" ESTIMABLE="YES" MEAN_1="48.33" MEAN_2="46.67" ORDER="24247" SD_1="18.63" SD_2="18.38" SE="7.554806968634826" STUDY_ID="STD-Treig-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="67.00666288052447"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.1978319302329" CI_START="-8.597831930232905" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.799999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.25" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.42979131885179545" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7895488130030158">
<NAME>Intention-to-treat analysis of neurological function at final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.1978319302329" CI_START="-8.597831930232905" EFFECT_SIZE="5.799999999999997" ESTIMABLE="YES" MEAN_1="37.4" MEAN_2="31.6" ORDER="24248" SD_1="21.82" SD_2="25.82" SE="7.345967601344292" STUDY_ID="STD-Martinsson-2003" TOTAL_1="15" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="48.36220254342747" CI_START="-11.082202543427467" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="18.64" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.2190069754564563" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.2291729934363627">
<NAME>Intention-to-treat analysis of relative change in neurological function until final follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="48.36220254342747" CI_START="-11.082202543427467" EFFECT_SIZE="18.64" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-23.97" ORDER="24249" SD_1="42.8" SD_2="56.88" SE="15.16466770709687" STUDY_ID="STD-Martinsson-2003" TOTAL_1="15" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.909562892559794" CI_START="-22.56956289255979" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.329999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.27" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.5445365995860868" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.605967106167582">
<NAME>Intention-to-treat analysis of language function at follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.909562892559794" CI_START="-22.56956289255979" EFFECT_SIZE="-5.329999999999998" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="58.33" ORDER="24250" SD_1="19.74" SD_2="20.22" SE="8.795856979282917" STUDY_ID="STD-Walker_x002d_Batson-2001" TOTAL_1="9" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.7176453266919083" CI_START="-14.102354673308085" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.409999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.28" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.029996393909539523" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="12" UNITS="" WEIGHT="99.99999999999999" Z="2.1701379909476297">
<NAME>Intention-to-treat analysis of relative change in language function until follow up</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7176453266919083" CI_START="-14.102354673308085" EFFECT_SIZE="-7.409999999999997" ESTIMABLE="YES" MEAN_1="17.67" MEAN_2="25.08" ORDER="24251" SD_1="8.06" SD_2="7.3" SE="3.4145294128343826" STUDY_ID="STD-Walker_x002d_Batson-2001" TOTAL_1="9" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.318502162254745" CI_START="-10.318502162254745" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.29" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.6374764822643582" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.4712300234610512">
<NAME>Intention-to-treat analysis of depression at final follow up (same as Depression at final follow up)</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.318502162254745" CI_START="-10.318502162254745" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="39.0" ORDER="24252" SD_1="10.4" SD_2="9.0" SE="4.244211744639202" STUDY_ID="STD-Reding-1995" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-07-16 10:30:43 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2008-07-16 10:30:43 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-07-16 10:30:03 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-16 10:30:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>The following strategy, using a combination of controlled vocabulary and text word terms, was used for MEDLINE and was modified to suit other databases.</P>
<P>Database MEDLINE (Ovid)<BR/>1 Exp cerebrovascular disorders/<BR/>2 (stroke$ or poststroke).tw<BR/>3 cerebrovascular$.tw<BR/>4 (cerebral or cerebellar or brain$).tw<BR/>5 (infarct$ or ischaemi$ or ischemi$ or thrombo$ or emboli$).tw<BR/>6 4 and 5<BR/>7 (cerebral or intracerebral or intracranial or brain$ or cerebellar).tw<BR/>8 (haemorrhage or hemorrhage).tw<BR/>9 7 and 8<BR/>10 1 or 2 or 3 or 6 or 9<BR/>11 Exp amphetamines/<BR/>12 (amphetamine$ or d-amphetamine or dexamphetamine or dextroamphetamine or methamphetamine).tw<BR/>13 11 or 12<BR/>14 10 and 13<BR/>15 Limit 14 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>